<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003478.pub5" GROUP_ID="NEONATAL" ID="005201041422063802" MERGED_FROM="" MODIFIED="2015-10-15 15:46:49 +0100" MODIFIED_BY="Colleen Ovelman" REVIEW_NO="" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2015-10-15 11:52:53 +0100" MODIFIED_BY="William McGuire">
<TITLE MODIFIED="2009-04-16 13:34:22 +0100" MODIFIED_BY="[Empty name]">Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants</TITLE>
<CONTACT>
<PERSON ID="15166" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Nicola</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Austin</LAST_NAME>
<SUFFIX/>
<POSITION>Neonatologist</POSITION>
<EMAIL_1>nicola.austin@cdhb.govt.nz</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>NICU</DEPARTMENT>
<ORGANISATION>Christchurch Womens Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Christchurch</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1>640303644699</PHONE_1>
<PHONE_2/>
<FAX_1>6433644883</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-10-15 11:52:53 +0100" MODIFIED_BY="William McGuire">
<PERSON ID="15166" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Nicola</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Austin</LAST_NAME>
<SUFFIX/>
<POSITION>Neonatologist</POSITION>
<EMAIL_1>nicola.austin@cdhb.govt.nz</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>NICU</DEPARTMENT>
<ORGANISATION>Christchurch Womens Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Christchurch</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1>640303644699</PHONE_1>
<PHONE_2/>
<FAX_1>6433644883</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1401221906428802904865575110076" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jemma</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cleminson</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>cleminsonjemma@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Academic Clinical Fellow in Child Health NIHR Centre for Reviews &amp; Dissemination</DEPARTMENT>
<ORGANISATION>University of York</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>York</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="4568" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Brian</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Darlow</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Paediatrics</POSITION>
<EMAIL_1>brian.darlow@otago.ac.nz</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Paediatrics</DEPARTMENT>
<ORGANISATION>Christchurch School of Medicine</ORGANISATION>
<ADDRESS_1>PO Box 4345</ADDRESS_1>
<ADDRESS_2/>
<CITY>Christchurch</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1>+64 3 3640 747</PHONE_1>
<PHONE_2>+64 3 3644 699</PHONE_2>
<FAX_1>+64 3 3644 907</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11151" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>William</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>McGuire</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Child Health</POSITION>
<EMAIL_1>William.McGuire@hyms.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Hull York Medical School &amp; Centre for Reviews and Dissemination, University of York</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>York</CITY>
<ZIP/>
<REGION>Y010 5DD</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>44 01904 321695</PHONE_1>
<PHONE_2/>
<FAX_1>44 01904 321696</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-09-03 18:05:57 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="3" MONTH="9" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="19" MONTH="5" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="8" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-09-08 21:01:23 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-09-03 18:06:19 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="9" YEAR="2015"/>
<DESCRIPTION>
<P>This updates the review "Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants" published in the Cochrane Library (<LINK REF="REF-Austin-2013" TYPE="REFERENCE">Austin 2013</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-09-08 21:01:23 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="9" YEAR="2015"/>
<DESCRIPTION>
<P>Updated search identified one new trial for inclusion (<LINK REF="STD-Mersal-2013" TYPE="STUDY">Mersal 2013</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-08-04 17:09:39 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-08-04 17:09:39 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Updated search identified new trials for inclusion (<LINK REF="STD-Violaris-2010" TYPE="STUDY">Violaris 2010</LINK>; <LINK REF="STD-Aydemir-2011a" TYPE="STUDY">Aydemir 2011a</LINK>; <LINK REF="STD-Aydemir-2011b" TYPE="STUDY">Aydemir 2011b</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2012-08-30 15:56:54 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="6" YEAR="2009"/>
<DESCRIPTION>
<P>Substantive update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2012-08-30 15:56:55 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="10" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-09-07 18:00:17 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2009-04-17 18:08:19 +0100" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>Christchurch Women's Hospital, Christchurch</NAME>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2009-04-17 18:08:19 +0100" MODIFIED_BY="[Empty name]">
<NAME>Centre for Reviews and Dissemination, University of York</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2015-09-07 18:00:17 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-08-04 17:13:14 +0100" MODIFIED_BY="[Empty name]">
<NAME>Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN275201100016C</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2015-09-07 18:00:17 +0100" MODIFIED_BY="[Empty name]">
<NAME>NIHR</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This report is independent research funded by a UK National Institute of Health Research Grant (NIHR) Cochrane Programme Grant (13/89/12). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR, or the UK Department of Health.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-10-15 12:10:14 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-10-15 12:07:18 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-09-05 19:01:26 +0100" MODIFIED_BY="[Empty name]">Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants</TITLE>
<SUMMARY_BODY MODIFIED="2015-10-15 12:07:18 +0100" MODIFIED_BY="[Empty name]">
<P>Review question: In very preterm or very low birth weight (VLBW) infants, does prophylactic oral/topical non-absorbed antifungal therapy reduce the risk of invasive fungal infection, mortality and adverse neurodevelopmental outcomes?</P>
<P>Background: Fungi such as candida (the organism that causes thrush) can cause bloddstream and other severe infections in VLBW infants (birth weight less than 1500 grams). These infections are often difficult to diagnose and frequently cause death or disability. Therefore, it may be appropriate to attempt to prevent such infections by giving VLBW infants antifungal drugs as a routine part of their care. This review assessed specifically the effect of giving infants antifungal drugs that reduce skin and gut carriage of fungi to reduce the chances of a severe infection developing.</P>
<P>Study characteristics: Four trials, in which a total of 1800 infants participated, examined whether giving VLBW infants a drug to prevent fungi growing on the skin or in the gut reduced the risk of bloodstream or other severe infection. The trials used one of two commonly available drugs (nystatin or miconazole) and compared these with either a placebo ("dummy" drug) or no drug. These trials, however, had some design weaknesses that make it less certain that their results can be taken at face value. </P>
<P>Key results: The overall analysis suggested that this treatment might reduce severe infection rates in VLBW infants but there was no evidence of a reduction in the risk of dying. </P>
<P>Conclusions: Larger and higher quality trials are needed to resolve this uncertainty.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-10-15 11:53:58 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-02-25 15:02:09 +0000" MODIFIED_BY="Kate Cahill">
<P>Invasive fungal infection is an important cause of mortality and morbidity in very preterm or very low birth weight infants. Uncertainty exists about the effect of prophylactic oral/topical non-absorbed antifungals to reduce mucocutaneous colonisation and so limit the risk of invasive fungal infection in this population.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-08-30 15:50:13 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effect of prophylactic oral/topical non-absorbed antifungal therapy on the incidence of invasive fungal infection, mortality and morbidity in very preterm or very low birth weight infants.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-09-09 16:53:54 +0100" MODIFIED_BY="Kate Cahill">
<P>We used the standard search strategy of the Cochrane Neonatal Review Group. This included searches of the Cochrane Central Register of Controlled Trials (CENTRAL: <I>The Cochrane Library</I>, 2015, Issue 7), MEDLINE, EMBASE, and CINAHL (to May 2015), conference proceedings, and previous reviews.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-08-30 15:50:27 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials or quasi-randomised controlled trials that compared the effect of prophylactic oral/topical non-absorbed antifungal therapy versus placebo or no drug or another antifungal agent or dose regimen in very preterm or very low birth weight infants.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-03-14 09:30:56 +0000" MODIFIED_BY="[Empty name]">
<P>We extracted data using the standard methods of the Cochrane Neonatal Review Group with separate evaluation of trial quality and data extraction by two review authors.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-10-15 11:53:58 +0100" MODIFIED_BY="[Empty name]">
<P>Four trials, in which a total of 1800 infants participated, compared oral/topical non-absorbed antifungal prophylaxis (nystatin or miconazole) with placebo or no drug. These trials had various methodological weaknesses including quasi-randomisation, lack of allocation concealment, and lack of blinding of intervention and outcomes assessment. The incidence of invasive fungal infection was very high in the control groups of three of these trials. Meta-analysis found a statistically significant reduction in the incidence of invasive fungal infection (typical risk ratio 0.20, 95% confidence interval 0.14 to 0.27; risk difference &#8722;0.18, &#8722;0.21 to &#8722;0.15) but substantial statistical heterogeneity was present. We did not find a statistically significant effect on mortality (typical risk ratio 0.87, 0.72 to 1.05; risk difference &#8722;0.03, &#8722;0.06 to 0.01). None of the trials assessed posthospital discharge outcomes. Three trials (N = 326) assessed the effect of oral/topical non-absorbed versus systemic antifungal prophylaxis. Meta-analyses did not find any statistically significant differences in the incidences of invasive fungal infection or all-cause mortality.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-12-23 20:25:13 +0000" MODIFIED_BY="[Empty name]">
<P>The finding of a reduction in risk of invasive fungal infection in very low birth weight infants treated with oral/topical non-absorbed antifungal prophylaxis should be interpreted cautiously because of methodological weaknesses in the included trials. Further large randomised controlled trials in current neonatal practice settings are needed to resolve this uncertainty. These trials might compare oral/topical non-absorbed antifungal agents with placebo, with each other, or with systemic antifungal agents and should include an assessment of effect on long-term neurodevelopmental outcomes.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-10-15 12:10:14 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-10-12 19:11:20 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2015-10-12 19:11:20 +0100" MODIFIED_BY="[Empty name]">
<P>Invasive fungal infection accounts for 10% of all cases of late-onset invasive infection in very preterm or very low birth weight (VLBW) infants (<LINK REF="REF-Stoll-2002" TYPE="REFERENCE">Stoll 2002</LINK>; <LINK REF="REF-Shane-2013" TYPE="REFERENCE">Shane 2013</LINK>). Invasive fungal infection is an important cause of morbidity and mortality in very preterm (less than 32 weeks) and VLBW (less than 1500 grams) infants (<LINK REF="REF-Kossoff-1998" TYPE="REFERENCE">Kossoff 1998</LINK>
<I>; </I>
<LINK REF="REF-Benjamin-2006" TYPE="REFERENCE">Benjamin 2006</LINK>
<I>; </I>
<LINK REF="REF-Robinson-2009" TYPE="REFERENCE">Robinson 2009</LINK>
<I>; </I>
<LINK REF="REF-Wynn-2012" TYPE="REFERENCE">Wynn 2012</LINK>). The reported mortality rates of greater than 25% are higher than those attributed to invasive bacterial infection in VLBW infants (<LINK REF="REF-Saiman-2000" TYPE="REFERENCE">Saiman 2000</LINK>; <LINK REF="REF-Makhoul-2002" TYPE="REFERENCE">Makhoul 2002</LINK>; <LINK REF="REF-Stoll-2002" TYPE="REFERENCE">Stoll 2002</LINK>; <LINK REF="REF-Benjamin-2003" TYPE="REFERENCE">Benjamin 2003</LINK>, <LINK REF="REF-Ascher-2012" TYPE="REFERENCE">Ascher 2012</LINK>). Invasive fungal infection is also associated with short- and long-term morbidity, including adverse neurodevelopmental outcomes (<LINK REF="REF-Lee-1998" TYPE="REFERENCE">Lee 1998</LINK>; <LINK REF="REF-Friedman-2000" TYPE="REFERENCE">Friedman 2000</LINK>; <LINK REF="REF-Saiman-2000" TYPE="REFERENCE">Saiman 2000</LINK>; <LINK REF="REF-Benjamin-2006" TYPE="REFERENCE">Benjamin 2006</LINK>; <LINK REF="REF-Wynn-2012" TYPE="REFERENCE">Wynn 2012</LINK>
; <LINK REF="REF-Adams_x002d_Chapman-2013" TYPE="REFERENCE">Adams-Chapman 2013</LINK>; <LINK REF="REF-Barton-2014" TYPE="REFERENCE">Barton 2014</LINK>).</P>
<P>The incidence of invasive fungal infection in VLBW infants is between about 1% and 4%, but the risk of infection is inversely related to gestational age and birth weight. In extremely preterm (less than 28 weeks) or extremely low birth weight (ELBW) infants (less than 1000 grams), reported incidences are between about 2% and 8%. Much higher incidences, up to 20%, have been reported for infants of birth weight less than 750 grams or gestational age at birth less than 26 weeks (<LINK REF="REF-Saiman-2000" TYPE="REFERENCE">Saiman 2000</LINK>; <LINK REF="REF-Makhoul-2002" TYPE="REFERENCE">Makhoul 2002</LINK>; <LINK REF="REF-Horbar-2002" TYPE="REFERENCE">Horbar 2002</LINK>; <LINK REF="REF-Karlowicz-2002" TYPE="REFERENCE">Karlowicz 2002</LINK>; <LINK REF="REF-Clerihew-2006" TYPE="REFERENCE">Clerihew 2006</LINK>; <LINK REF="REF-Vergnano-2011" TYPE="REFERENCE">Vergnano 2011</LINK>
<I>; </I>
<LINK REF="REF-Oeser-2014" TYPE="REFERENCE">Oeser 2014</LINK>). It has been reported that the incidence of invasive fungal infection in preterm and low birth weight infants is decreasing, especially among ELBW infants. This coincides with an increase in the use of antifungal prophylaxis, a reduction in the use of broad spectrum antibiotics, and the introduction of central venous catheter care bundles (<LINK REF="REF-Oeser-2013" TYPE="REFERENCE">Oeser 2013</LINK>
<I>; </I>
<LINK REF="REF-Aliaga-2014" TYPE="REFERENCE">Aliaga 2014</LINK>; <LINK REF="REF-Oeser-2014" TYPE="REFERENCE">Oeser 2014</LINK>
<I>).</I>
</P>
<P>Observational studies suggest that mucocutaneous or tracheal fungal colonisation is a risk factor for invasive infection (<LINK REF="REF-Faix-1989" TYPE="REFERENCE">Faix 1989</LINK>; <LINK REF="REF-Pappu_x002d_Katikaneni-1990" TYPE="REFERENCE">Pappu-Katikaneni 1990</LINK>; <LINK REF="REF-Rowen-1994" TYPE="REFERENCE">Rowen 1994</LINK>; <LINK REF="REF-Huang-1998" TYPE="REFERENCE">Huang 1998</LINK>). However, multivariate analyses that account for potential confounding variables have not confirmed this association (<LINK REF="REF-Saiman-2000" TYPE="REFERENCE">Saiman 2000</LINK>). Other putative risk factors for invasive fungal infection in VLBW infants include severity of illness at birth, the use of multiple courses of antibiotics (particularly third-generation cephalosporins), the use of parenteral nutrition, the presence of a central venous catheter, and exposure to histamine receptor subtype 2 antagonists (<LINK REF="REF-Rowen-1994" TYPE="REFERENCE">Rowen 1994</LINK>; <LINK REF="REF-Benjamin-2006" TYPE="REFERENCE">Benjamin 2006</LINK>; <LINK REF="REF-Cotten-2006" TYPE="REFERENCE">Cotten 2006</LINK>; <LINK REF="REF-Manzoni-2006" TYPE="REFERENCE">Manzoni 2006</LINK>; <LINK REF="REF-Barton-2014" TYPE="REFERENCE">Barton 2014</LINK>
;
 
<LINK REF="REF-Oeser-2014" TYPE="REFERENCE">Oeser 2014</LINK>).</P>
<P>The clinical presentation of invasive fungal infection in VLBW infants is similar to that of bacterial infection and this may cause delays in diagnosis and treatment. The diagnosis may be further delayed due to an inability to recover the organism from microbiological culture of blood, cerebrospinal fluid, or urine. A high index of suspicion and the use of additional laboratory and clinical tests may be needed to confirm the suspected diagnosis (<LINK REF="REF-Benjamin-2003" TYPE="REFERENCE">Benjamin 2003</LINK>; <LINK REF="REF-Oeser-2014" TYPE="REFERENCE">Oeser 2014</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-10-12 12:05:26 +0100" MODIFIED_BY="[Empty name]">
<P>Given the difficulty in establishing an early diagnosis and the high level of associated morbidity and mortality, there is a need to assess the effect of strategies to prevent invasive fungal infection in VLBW infants (<LINK REF="REF-Brecht-2009" TYPE="REFERENCE">Brecht 2009</LINK>). In addition to generic infection control practices and avoidance of modifiable risk factors, two broad chemoprophylactic strategies are employed in current clinical practice (<LINK REF="REF-Burwell-2006" TYPE="REFERENCE">Burwell 2006</LINK>; <LINK REF="REF-Clerihew-2008" TYPE="REFERENCE">Clerihew 2008</LINK>; <LINK REF="REF-Ganesan-2008" TYPE="REFERENCE">Ganesan 2008</LINK>; <LINK REF="REF-O_x0027_Grady-2008" TYPE="REFERENCE">O'Grady 2008</LINK>; <LINK REF="REF-Howell-2009" TYPE="REFERENCE">Howell 2009</LINK>; <LINK REF="REF-Kaguelidou-2012" TYPE="REFERENCE">Kaguelidou 2012</LINK>):</P>
<UL>
<LI>Prophylaxis using systemically-absorbed antifungal drugs that achieve fungicidal concentrations in tissue, blood, cerebrospinal fluid, and urine. Evidence exists that systemic antifungal prophylaxis using fluconazole reduces the incidence of invasive fungal infection, but there is concern about toxicity (<LINK REF="REF-Frattarelli-2004" TYPE="REFERENCE">Frattarelli 2004</LINK>); as well as the effect that its widespread use may have on the emergence of antifungal resistance (<LINK REF="REF-Brion-2007" TYPE="REFERENCE">Brion 2007</LINK>; <LINK REF="REF-Austin-2007" TYPE="REFERENCE">Austin 2007</LINK>).</LI>
</UL>
<UL>
<LI>Prophylaxis using oral/topical non-absorbed agents such as nystatin or miconazole. Observational studies have suggested that oral/topical non-absorbed antifungal prophylaxis reduces mucocutaneous fungal colonisation and the risk of invasive infection in VLBW infants (<LINK REF="REF-Ganesan-2008" TYPE="REFERENCE">Ganesan 2008</LINK>; <LINK REF="REF-Howell-2009" TYPE="REFERENCE">Howell 2009</LINK>). However, the specific effect of antifungal prophylaxis independently of other confounding interventions and variables is unable to be determined from these studies. Another concern is that hyper-osmolar nystatin preparations may increase the risk of adverse gastrointestinal events in VLBW infants (<LINK REF="REF-Ernst-1983" TYPE="REFERENCE">Ernst 1983;</LINK> <LINK REF="REF-Radmacher-2012" TYPE="REFERENCE">Radmacher 2012</LINK>).</LI>
</UL>
</INTERVENTION>
<IMPORTANCE MODIFIED="2014-08-24 15:43:11 +0100" MODIFIED_BY="Kate Cahill">
<P>This review focuses on randomised comparisons of oral/topical non-absorbed antifungal prophylaxis compared with no antifungal prophylaxis or compared with systemic antifungal prophylaxis. The effect of systemic antifungal prophylaxis compared with no prophylaxis is addressed in another Cochrane review (<LINK REF="REF-Austin-2007" TYPE="REFERENCE">Austin 2007</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-10-12 19:11:33 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effect of prophylactic oral/topical non-absorbed antifungal therapy on the incidence of invasive fungal infection, mortality and adverse neurodevelopmental outcomes in very preterm or VLBW infants.</P>
<P>We examined the following interventions:</P>
<OL>
<LI>oral/topical antifungal prophylaxis versus placebo or no drug;</LI>
<LI>oral/topical antifungal prophylaxis versus systemic antifungal prophylaxis;</LI>
<LI>one oral/topical antifungal regimen versus another oral/topical antifungal regimen.</LI>
</OL>
<P>We pre-specified these subgroup analyses:</P>
<OL>
<LI>extremely preterm (less than 28 weeks) or ELBW infants (less than 1000 grams);</LI>
<LI>trials in which participants were infants with fungal colonisation.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2015-10-12 19:12:57 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-10-12 19:11:44 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-04-15 10:04:39 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised or quasi-randomised controlled trials, including cluster randomised trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-10-12 19:11:44 +0100" MODIFIED_BY="[Empty name]">
<P>VLBW infants (less than 1500 grams) or very preterm infants (less than 32 weeks at birth).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-03-14 09:42:14 +0000" MODIFIED_BY="[Empty name]">
<P>Antifungal prophylaxis with oral/topical non-absorbed drugs versus placebo or nothing or another antifungal drug regimen.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-10-12 12:13:41 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-10-12 12:11:30 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Confirmed invasive fungal infection as determined by:</LI>
<OL>
<LI>culture of fungus from a normally sterile site: cerebrospinal fluid, blood, urine, bone or joint, peritoneum, pleural space. Samples should have been collected using methods to minimise contamination with surface-colonising organisms;</LI>
<LI>findings on autopsy examination consistent with invasive fungal infection;</LI>
<LI>findings on ophthalmological examination consistent with fungal ophthalmitis or retinitis;</LI>
<LI>pathognomonic findings on renal ultrasound examination such as 'renal fungal balls'.</LI>
</OL>
<LI>Death prior to hospital discharge.</LI>
<LI>Neurodevelopmental outcomes assessed beyond infancy (neurological evaluations, developmental scores, and classifications of disability, including auditory and visual disability, non-ambulant cerebral palsy, developmental delay); and cognitive and educational outcomes at five years or older (intelligence quotient and/or indices of educational achievement measured using a validated tool including school examination results).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-10-12 12:13:41 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Bronchopulmonary dysplasia (oxygen supplementation at 36 weeks postmenstrual age);</LI>
<LI>Necrotising enterocolitis (Bell stage 2 or 3);</LI>
<LI>Retinopathy of prematurity: a) any stage; b) requiring treatment;</LI>
<LI>Duration of intensive care unit or hospital admission (days);</LI>
<LI>Emergence of organisms resistant to antifungal agents, as detected in individual infants enrolled in the study or, in the case of cluster randomised studies, on surveillance of other infants in the same unit in the study centre (including infants who were admitted to the unit following completion of the study);</LI>
<LI>Adverse drug reactions attributed to the antifungal agent, such as rash (including Stevens&#8211;Johnson reactions), gastrointestinal disturbance, abnormal hepatic or renal function, cardiac arrhythmias, thrombophlebitis, seizures, and anaphylaxis or toxicity sufficient to cease drug administration.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-10-12 12:21:12 +0100" MODIFIED_BY="[Empty name]">
<P>We used the standard search strategy of the Cochrane Neonatal Review Group.</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-10-12 12:20:04 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I>, 2015, Issue 7), MEDLINE (1966 to May 2015), EMBASE (1980 to May 2015), and CINAHL (1982 to May 2015), using a combination of the following text words and MeSH terms: [Infant, Newborn OR Infant, Premature OR Infant, Low Birth Weight OR LBW OR infan* OR neonat*] AND [Mycoses/ OR fung* OR candid* OR Candida albicans OR Antifungal Agents/ OR Triazoles/ OR fluconazole OR azole OR amphotericin B OR nystatin OR nystan OR mycostatin OR nilstat OR nystex OR miconazole OR daktarin OR ketoconazole OR clotrimazole]. The search outputs were limited with the relevant search filters for clinical trials as recommended in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We did not apply any language restriction [See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for search strategy].</P>
<P>We searched <A HREF="http://clinicaltrials.gov/">ClinicalTrials.gov</A> and <A HREF="http://www.controlled-trials.com/">Current Controlled Trials</A> for completed or ongoing trials.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-10-12 12:21:12 +0100" MODIFIED_BY="[Empty name]">
<P>We examined the references in studies identified as potentially relevant. We also searched the abstracts from the annual meetings of the Pediatric Academic Societies (1993 to 2015), the European Society for Paediatric Research (1995 to 2014), the UK Royal College of Paediatrics and Child Health (2000 to 2015), and the Perinatal Society of Australia and New Zealand (2000 to 2015). We considered trials reported only as abstracts to be eligible if sufficient information was available from the report, or from contact with the authors, to fulfil the inclusion criteria.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-10-12 19:12:57 +0100" MODIFIED_BY="[Empty name]">
<P>We used the standard methods of the Cochrane Neonatal Review Group.</P>
<STUDY_SELECTION MODIFIED="2013-02-25 15:01:03 +0000" MODIFIED_BY="Kate Cahill">
<P>Two review authors screened the title and abstract of all studies identified by the above search strategy. We reassessed the full text of any potentially eligible reports and excluded those studies that did not meet all of the inclusion criteria. We discussed any disagreements until we achieved consensus.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-02-25 15:01:03 +0000" MODIFIED_BY="Kate Cahill">
<P>We used a data collection form to aid extraction of relevant information from each included study. Two review authors extracted the data separately. We discussed any disagreements until we achieved consensus. We asked the investigators for further information if data from the trial reports were insufficient.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-10-12 19:12:52 +0100" MODIFIED_BY="[Empty name]">
<P>We used the criteria and standard methods of Cochrane and the Cochrane Neonatal Group to assess the methodological quality of any included trials. We requested additional information from the trial authors to clarify methodology and results as necessary. We evaluated and reported the following issues in the 'Risk of bias' tables:</P>
<P>Sequence generation (the method used to generate the allocation sequence):</P>
<UL>
<LI>low risk: any truly random process, e.g. random number table; computer random number generator;</LI>
<LI>high risk: any non-random process, e.g. odd or even date of birth; hospital or clinic record number;</LI>
<LI>unclear risk: no or unclear information provided.</LI>
</UL>
<P>Allocation concealment (the method used to conceal the allocation sequence):</P>
<UL>
<LI>low risk: e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes;</LI>
<LI>high risk: open random allocation, e.g. unsealed or non-opaque envelopes, alternation; date of birth;</LI>
<LI>unclear: no or unclear information provided.</LI>
</UL>
<P>Blinding (the methods used to ensure blinding of participants, clinicians and caregivers, and outcome assessors):</P>
<UL>
<LI>low risk;</LI>
<LI>high risk;</LI>
<LI>unclear.</LI>
</UL>
<P>Incomplete outcome data (completeness of data including attrition and exclusions from the analysis for each outcome and any reasons for attrition or exclusion where reported): We will assess whether missing data are balanced across groups or are related to outcomes. Where sufficient information is reported or supplied by the trial authors, we will reinstate missing data in the analyses. We will categorise completeness as:</P>
<UL>
<LI>low risk: adequate (less than 10% missing data);</LI>
<LI>high risk: inadequate (more than 10% missing data);</LI>
<LI>unclear risk: no or unclear information provided.</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-10-12 14:00:11 +0100" MODIFIED_BY="[Empty name]">
<P>We calculated risk ratio (RR) and risk difference (RD) for dichotomous data and weighted mean difference (WMD) for continuous data, with respective 95% confidence intervals (CI). We determined the number needed to treat for an additional beneficial outcome (NNTB) or for an additional harmful outcome (NNTH) for analyses with a statistically significant difference in the RD.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-02-25 15:02:09 +0000" MODIFIED_BY="Kate Cahill">
<P>The unit of analysis is the participating infant in individually randomised trials, and the neonatal unit for cluster randomised trials.</P>
</UNIT_OF_ANALYSIS>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-10-12 19:12:57 +0100" MODIFIED_BY="[Empty name]">
<P>We examined the treatment effects of individual trials and heterogeneity between trial results by inspecting the forest plots. We calculated the I² statistic for each RR analysis to quantify inconsistency across studies and describe the percentage of variability in effect estimates that may be due to heterogeneity rather than to sampling error. If we detected substantial heterogeneity (I² more than 50%), we explored the possible causes (for example, differences in study design, participants, interventions, or completeness of outcome assessments).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-03-14 09:53:21 +0000" MODIFIED_BY="[Empty name]">
<P>If more than five trials were included in a meta-analysis, we examined a funnel plot for asymmetry.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-09-07 18:01:10 +0100" MODIFIED_BY="Kate Cahill">
<P>We used the fixed-effect model in Review Manager 5.3 for meta-analysis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-10-12 19:11:56 +0100" MODIFIED_BY="[Empty name]">
<P>We prespecified the following subgroup analyses:</P>
<OL>
<LI>extremely preterm (less than 28 weeks) or ELBW infants (less than 1000 grams);</LI>
<LI>infants with fungal colonisation at trial entry.</LI>
</OL>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-10-15 12:10:14 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-10-15 12:09:19 +0100" MODIFIED_BY="[Empty name]">
<P>We included seven eligible trials: <LINK REF="STD-Sims-1988" TYPE="STUDY">Sims 1988</LINK>; <LINK REF="STD-Wainer-1992" TYPE="STUDY">Wainer 1992</LINK>: <LINK REF="STD-Ozturk-2006" TYPE="STUDY">Ozturk 2006</LINK>; <LINK REF="STD-Violaris-2010" TYPE="STUDY">Violaris 2010</LINK>; <LINK REF="STD-Aydemir-2011a" TYPE="STUDY">Aydemir 2011a</LINK>; <LINK REF="STD-Aydemir-2011b" TYPE="STUDY">Aydemir 2011b</LINK>; <LINK REF="STD-Mersal-2013" TYPE="STUDY">Mersal 2013</LINK> (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-10-15 12:09:19 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Oral/topical non-absorbed antifungal prophylaxis versus placebo or no drug (comparison 1):</HEADING>
<P>Four trials compared oral/topical non-absorbed antifungal prophylaxis with placebo or no drug:</P>
<P>
<LINK REF="STD-Sims-1988" TYPE="STUDY">Sims 1988</LINK> quasi-randomly allocated 67 infants of birth weight less than 1250 grams to receive either oral nystatin or no treatment until one week after endotracheal extubation (average five weeks).</P>
<P>
<LINK REF="STD-Wainer-1992" TYPE="STUDY">Wainer 1992</LINK> recruited 600 infants of birth weight less than 1750 grams. We made a consensus decision to include the trial because most participating infants were less than 1500 grams. Participants were randomised to receive either oral miconazole or placebo until discharge. The study was undertaken in the late 1980s in South Africa. Due to limited resources mechanical ventilation was not offered to ELBW infants (12% of the participants).</P>
<P>
<LINK REF="STD-Ozturk-2006" TYPE="STUDY">Ozturk 2006</LINK> randomly allocated 938 VLBW infants to receive either prophylactic oral nystatin (100,000 IU three times daily) or no treatment. Infants in the control group who had oral fungal colonisation detected at trial entry or on surveillance cultures were treated with nystatin (100,000 IU three times daily).</P>
<P>
<LINK REF="STD-Aydemir-2011a" TYPE="STUDY">Aydemir 2011a</LINK> randomly allocated 185 VLBW infants to receive either oral nystatin 100,000 IU three times daily or "equal volumes of intravenous or oral normal saline" placebo every third day until the 30th day after birth (or 45th day in ELBW infants).</P>
<P>The primary outcomes of all studies were fungal colonisation and invasive fungal infection. All provided data on in-hospital mortality but none assessed any postdischarge outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Oral/topical non-absorbed versus systemic antifungal prophylaxis (comparison 2):</HEADING>
<P>Two trials compared oral/topical antifungal prophylaxis with systemic antifungal prophylaxis:</P>
<P>
<LINK REF="STD-Violaris-2010" TYPE="STUDY">Violaris 2010</LINK> randomised 80 VLBW infants to receive either oral nystatin or fluconazole beginning between days five to seven after birth. Outcome data on invasive fungal infection and mortality were reported.</P>
<P>
<LINK REF="STD-Aydemir-2011b" TYPE="STUDY">Aydemir 2011b</LINK> randomly allocated 187 VLBW infants to receive either oral nystatin 100,000 IU eight hourly or intravenous fluconazole 3 mg/kg every third day until 30 days after birth (or 45 days after birth in ELBW infants).</P>
<P>
<LINK REF="STD-Mersal-2013" TYPE="STUDY">Mersal 2013</LINK> randomly allocated 59 preterm infants of birth weight less than 1200 grams to receive either oral nystatin 100,000 IU eight hourly for six weeks (N = 24) or intravenous fluconazole 6 mg/kg every 72 hours at end of first week of life, then every 48 hours from second week to sixth week of life (N = 35).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">One oral/topical non-absorbed antifungal regimen versus another oral/topical non-absorbed antifungal regimen (comparison 3):</HEADING>
<P>We did not find any trials that compared different dose regimens of oral/topical non-absorbed antifungal prophylaxis.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-09-07 17:56:45 +0100" MODIFIED_BY="[Empty name]">
<P>We excluded five studies (<LINK REF="STD-Harris-1960" TYPE="STUDY">Harris 1960</LINK>; <LINK REF="STD-Damjanovic-1993" TYPE="STUDY">Damjanovic 1993</LINK>; <LINK REF="STD-Herruzo_x002d_Cabrera-1994" TYPE="STUDY">Herruzo-Cabrera 1994</LINK>; <LINK REF="STD-Demirel-2013" TYPE="STUDY">Demirel 2013</LINK>; <LINK REF="STD-Oncel-2015" TYPE="STUDY">Oncel 2015</LINK>: see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-09-07 17:57:12 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessments are described in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and displayed in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>. One trial was quasi-randomised and lacked allocation concealment (<LINK REF="STD-Sims-1988" TYPE="STUDY">Sims 1988</LINK>). The most common methodological weakness was lack of blinding of caregivers and investigators and assessors to the nature of the intervention. Only one trial is likely to have been truly placebo-controlled (<LINK REF="STD-Wainer-1992" TYPE="STUDY">Wainer 1992</LINK>). All of the trials reported complete or near-complete assessment for primary outcomes.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-10-15 12:10:14 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Oral/topical non-absorbed antifungal prophylaxis versus placebo or no drug (comparison 1):</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes:</HEADING>
<P>
<B>Invasive fungal infection (Outcome 1.1): </B>Meta-analysis of data from four trials found a statistically significant reduction in the intervention group but with significant and substantial statistical heterogeneity (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>): typical RR 0.20 (95% CI 0.14 to 0.27), I² = 80%; typical RD &#8722;0.18 (95% CI &#8722;0.21 to &#8722;0.15); NNTB five infants.</P>
<P>Forest plot inspection suggested that the direction of the effect size estimate from <LINK REF="STD-Wainer-1992" TYPE="STUDY">Wainer 1992</LINK> was inconsistent with those of the other three trials. Meta-analysis omitting data from <LINK REF="STD-Wainer-1992" TYPE="STUDY">Wainer 1992</LINK> removed heterogeneity, but did not change the pooled effect size estimate [revised typical RR 0.16 (95% CI 0.11 to 0.23), I² = 0%].</P>
<P>
<B>Death prior to hospital discharge (Outcome 1.2): </B>None of the individual trials or a meta-analysis of data from all four trials found a statistically significant effect. We found no evidence of statistical heterogeneity (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>): typical RR 0.87 (95% CI 0.72 to 1.05), I² = 0%; typical RD &#8722;0.03 (95% CI &#8722;0.06 to 0.01).</P>
<P>
<B>Neurodevelopmental outcomes:</B> Not reported by any trials. 
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes:</HEADING>
<P>
<B>Bronchopulmonary dysplasia (Outcome 1.3): </B>
<LINK REF="STD-Aydemir-2011a" TYPE="STUDY">Aydemir 2011a</LINK> did not find a statistically significant difference: RR 1.29 (95% CI 0.67 to 2.49). Outcome not reported in the other trials.</P>
<P>
<B>Necrotising enterocolitis (Outcome 1.4): </B>
<LINK REF="STD-Aydemir-2011a" TYPE="STUDY">Aydemir 2011a</LINK> did not find a statistically significant difference: RR 0.97 (95% CI 0.40 to 2.33). Outcome not reported in the other trials.</P>
<P>
<B>Retinopathy of prematurity (Outcome 1.5): </B>
<LINK REF="STD-Aydemir-2011a" TYPE="STUDY">Aydemir 2011a</LINK> did not find a statistically significant difference in the incidence of retinopathy requiring surgery: RR 0.62 (95% CI 0.30 to 1.28). Outcome not reported in the other trials.</P>
<P>
<B>Duration of intensive care unit stay (Outcome 1.6): </B>Three trials reported length of stay in intensive care (<LINK REF="STD-Sims-1988" TYPE="STUDY">Sims 1988</LINK>; <LINK REF="STD-Wainer-1992" TYPE="STUDY">Wainer 1992</LINK>; <LINK REF="STD-Aydemir-2011a" TYPE="STUDY">Aydemir 2011a</LINK>). None of the trials individually, or a meta-analysis of data from all trials, found a statistically significant difference: WMD &#8722;0.52 (95% CI &#8722;4.34 to 3.29) days (I² = 0%) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<P>
<B>Adverse events attributed to drug reactions or toxicity sufficient to cease drug administration:</B> Not reported by any trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analyses</HEADING>
<OL>
<LI>Extremely preterm or ELBW infants: Data were available from one trial (<LINK REF="STD-Ozturk-2006" TYPE="STUDY">Ozturk 2006</LINK>).</LI>
<OL>
<LI>invasive fungal infection: <LINK REF="STD-Ozturk-2006" TYPE="STUDY">Ozturk 2006</LINK> found a statistically significant reduction: RR 0.12 (95% CI 0.06 to 0.26); RD &#8722;0.27 (95% CI &#8722;0.35 to &#8722;0.20).</LI>
<LI>mortality: <LINK REF="STD-Ozturk-2006" TYPE="STUDY">Ozturk 2006</LINK> did not find a statistically significant effect: RR 1.07 (95% CI 0.51 to 2.25); RD 0.01 (95% CI &#8722;0.05 to 0.06).</LI>
</OL>
<LI>Trials in which participants were infants with fungal colonisation: None of the trials restricted participation to infants with fungal colonisation at trial entry.</LI>
</OL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral/topical non-absorbed versus systemic antifungal prophylaxis (comparison 2):</HEADING>
<P>Three trials compared oral or topical antifungal prophylaxis (nystatin) with systemic antifungal prophylaxis (fluconazole) (<LINK REF="STD-Violaris-2010" TYPE="STUDY">Violaris 2010</LINK>; <LINK REF="STD-Aydemir-2011b" TYPE="STUDY">Aydemir 2011b</LINK>; <LINK REF="STD-Mersal-2013" TYPE="STUDY">Mersal 2013</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes:</HEADING>
<P>
<B>Invasive fungal infection (Outcome 2.1): </B>Meta-analysis did not detect a statistically significant difference (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>): typical RR 1.89 (95% CI 0.66 to 5.39), I² = 0%; typical RD 0.03 (95% CI &#8722;0.02 to 0.07).</P>
<P>
<B>Death prior to hospital discharge (Outcome 2.2): </B>Meta-analysis did not detect a statistically significant difference (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>): typical RR 1.39 (95% CI 0.64 to 3.00), I² = 46%; typical RD 0.02 (95% CI &#8722;0.03 to 0.08).</P>
<P>
<B>Neurodevelopmental outcomes: </B>None of the trials reported any neurodevelopmental outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes:</HEADING>
<P>
<B>Bronchopulmonary dysplasia in surviving infants:</B> <LINK REF="STD-Aydemir-2011b" TYPE="STUDY">Aydemir 2011b</LINK> did not find a statistically significant difference: RR 1.29 [95% CI 0.67 to 2.49]; RD 0.04 [95% CI &#8722;0.07 to 0.16]. Not reported by <LINK REF="STD-Violaris-2010" TYPE="STUDY">Violaris 2010</LINK> or <LINK REF="STD-Mersal-2013" TYPE="STUDY">Mersal 2013</LINK>.</P>
<P>
<B>Necrotising enterocolitis: </B>Meta-analysis of data from <LINK REF="STD-Violaris-2010" TYPE="STUDY">Violaris 2010</LINK> and <LINK REF="STD-Aydemir-2011b" TYPE="STUDY">Aydemir 2011b</LINK> did not detect a statistically significant difference (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>): typical RR 1.22 (95% CI 0.58 to 2.60), I² = 0%; RD 0.02 (95% CI &#8722;0.05 to 0.09). Not reported by <LINK REF="STD-Mersal-2013" TYPE="STUDY">Mersal 2013</LINK>.</P>
<P>
<B>Retinopathy of prematurity:</B> <LINK REF="STD-Aydemir-2011b" TYPE="STUDY">Aydemir 2011b</LINK> did not find a statistically significant difference in the incidence of retinopathy requiring surgery in surviving infants: RR 1.24 [95% CI 0.51 to 2.98]; RD 0.02 [95% CI &#8722;0.07 to 0.11]. Not reported by <LINK REF="STD-Violaris-2010" TYPE="STUDY">Violaris 2010</LINK> or <LINK REF="STD-Mersal-2013" TYPE="STUDY">Mersal 2013</LINK>.</P>
<P>
<B>Duration of intensive care unit stay:</B> <LINK REF="STD-Aydemir-2011b" TYPE="STUDY">Aydemir 2011b</LINK> did not find a statistically significant difference: MD &#8722;1.00 (95% CI &#8722;7.63 to 5.63) days. Not reported by <LINK REF="STD-Violaris-2010" TYPE="STUDY">Violaris 2010</LINK> or <LINK REF="STD-Mersal-2013" TYPE="STUDY">Mersal 2013</LINK>.</P>
<P>
<B>Adverse events attributed to drug reactions or toxicity sufficient to cease drug administration:</B> Not reported by any of the trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analyses</HEADING>
<OL>
<LI>Extremely preterm or ELBW infants: None of the trials provided subgroup data.</LI>
<LI>Trials in which participants were infants with fungal colonisation: None of the trials restricted participation to infants with fungal colonisation at trial entry.
</LI>
</OL>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-10-12 14:17:34 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2015-10-12 14:15:29 +0100" MODIFIED_BY="[Empty name]">
<P>Meta-analysis of data from four trials suggests that oral/topical non-absorbed prophylaxis reduces the risk of invasive fungal infection in VLBW infants significantly and substantially. None of the trials or a meta-analysis of their data found a statistically significant effect on mortality. Meta-analysis of data from three trials did not detect an effect on the duration of intensive care. The trials reported only limited data on other neonatal morbidities that may be associated with invasive fungal infection. None of the trials assessed long-term neurodevelopmental outcomes.</P>
<P>Three trials assessed the effect of oral/topical non-absorbed antifungal prophylaxis (nystatin) versus systemic antifungal prophylaxis (fluconazole). Meta-analyses did not find any statistically significant effects on the incidence of invasive fungal infection or all-cause mortality but much larger studies would be needed to exclude more modest but important effect sizes.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-10-12 14:16:44 +0100" MODIFIED_BY="[Empty name]">
<P>The finding that oral/topical non-absorbed antifungal prophylaxis reduces the risk of invasive fungal infection in VLBW infants should be interpreted and applied with caution. The existence of substantial statistical heterogeneity in the meta-analysis raises concern that the estimate of effect is not robust. The applicability of the finding is also limited by the very high incidence of invasive fungal infection in the control populations in the three trials that found a statistically significant effect on the incidence of invasive fungal infection (<LINK REF="STD-Sims-1988" TYPE="STUDY">Sims 1988</LINK>; <LINK REF="STD-Ozturk-2006" TYPE="STUDY">Ozturk 2006</LINK>; <LINK REF="STD-Aydemir-2011a" TYPE="STUDY">Aydemir 2011a</LINK>). About one-sixth to one-third of infants in the control groups developed invasive fungal infection, much higher than the less than 5% incidence estimated in large cohort studies (<LINK REF="REF-Saiman-2000" TYPE="REFERENCE">Saiman 2000</LINK>; <LINK REF="REF-Horbar-2002" TYPE="REFERENCE">Horbar 2002</LINK>; <LINK REF="REF-Karlowicz-2002" TYPE="REFERENCE">Karlowicz 2002</LINK>; <LINK REF="REF-Makhoul-2002" TYPE="REFERENCE">Makhoul 2002</LINK>; <LINK REF="REF-Clerihew-2006" TYPE="REFERENCE">Clerihew 2006</LINK>; <LINK REF="REF-Howell-2009" TYPE="REFERENCE">Howell 2009</LINK>). This limits the applicability of the NNTB estimate (five infants), since in clinical settings with lower incidences of invasive fungal infection a much larger number of infants would need treatment to prevent a single extra case of invasive fungal infection.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-10-12 14:17:34 +0100" MODIFIED_BY="[Empty name]">
<P>The largest trial (N = 948) contributed 84% of the weighted estimate of risk ratio effect on invasive fungal infection (<LINK REF="STD-Ozturk-2006" TYPE="STUDY">Ozturk 2006</LINK>). This trial of nystatin prophylaxis was undertaken in Turkey within the past decade. More than one-third of participants were ELBW infants receiving intensive care interventions. The criteria for diagnosing invasive fungal infection appear to be have been robust. Efforts to limit contamination of microbiological cultures by surface colonising organisms were made; for example, fungal urinary tract infection was based on culture of organisms from two separate supra-pubic bladder aspirates. However, caregivers or assessors were not blinded to the intervention and this may have caused surveillance and ascertainment bias if thresholds for investigation and diagnosis of suspected invasive fungal infection were adjusted according to treatment status. Although 25% of control VLBW infants received nystatin to treat oral fungal colonisation detected at trial entry or during the trial period, this is likely to have reduced the effect size of the primary intervention.</P>
<P>The second largest trial (N = 600) did not detect a statistically significant effect of miconazole prophylaxis on the incidence of invasive fungal infection (<LINK REF="STD-Wainer-1992" TYPE="STUDY">Wainer 1992</LINK>). This trial was placebo-controlled and therefore less prone to surveillance bias. The trial was undertaken in South Africa 25 years ago in a settling with few intensive care resources. Twelve per cent of participants were ELBW and the overall incidence of invasive fungal infection was 2% in the control group. This lower incidence may be related to the fact that because of resource limitations ELBW infants did not receive intensive care interventions. Two-thirds of ELBW infants died. The applicability of the trial's findings to modern neonatal intensive care settings in high-income countries is therefore likely to be limited.</P>
<P>A subgroup analysis of outcomes for infants colonised with fungi at trial entry was not possible. None of the trials prespecified fungal colonisation as an entry criterion. Between 25% and 45% of participating infants had fungal colonisation, but subgroup data for these infants were not available in the published reports of the included trials. Even if these data become available for analysis, those from the largest trial would be of limited value since infants in the control group received antifungal treatment if oral fungal colonisation was detected (<LINK REF="STD-Ozturk-2006" TYPE="STUDY">Ozturk 2006</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-02-25 15:02:09 +0000" MODIFIED_BY="Kate Cahill">
<P>The existence of substantial statistical heterogeneity in the meta-analysis of the effect of oral/topical non-absorbed antifungal prophylaxis versus placebo or no drug on the incidence of invasive fungal infection raises concern that the estimate is not robust (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). The heterogeneity may be due to differences between the trials including population characteristics (proportion of ELBW infants), nature of the intervention (miconazole in one trial, nystatin in the others), methodological quality issues (particularly unblinded allocation and intervention) and the effect of other co-interventions (availability of intensive care for ELBW infants). Forest plot inspection suggested that the direction of the effect size estimate from <LINK REF="STD-Wainer-1992" TYPE="STUDY">Wainer 1992</LINK> was inconsistent with those of the other three trials. In a post hoc sensitivity analysis, removal of this trial from the meta-analysis removed statistical heterogeneity from the RR estimate and but did not change the direction or size of the estimate.</P>
</POTENTIAL_BIASES>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-10-12 14:23:53 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-02-25 15:01:49 +0000" MODIFIED_BY="Kate Cahill">
<P>The available trial data remain insufficient to guide clinical practice. Although meta-analysis suggests that oral/topical non-absorbed antifungal agents (nystatin or miconazole) reduce the risk of invasive fungal infection, methodological weaknesses limit the validity and applicability of this finding.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-10-12 14:23:53 +0100" MODIFIED_BY="[Empty name]">
<P>Further randomised controlled trials of oral/topical non-absorbed antifungal prophylaxis are needed to provide more valid and precise estimates of effect size. Because most neonatologists who currently use antifungal prophylaxis target infants thought to be at greatest risk, mainly ELBW or extremely preterm infants with additional risk factors, a trial restricted to this population of infants or even smaller or lower gestation infants may be appropriate and acceptable (<LINK REF="REF-Burwell-2006" TYPE="REFERENCE">Burwell 2006</LINK>; <LINK REF="REF-Clerihew-2008" TYPE="REFERENCE">Clerihew 2008</LINK>; <LINK REF="REF-Howell-2009" TYPE="REFERENCE">Howell 2009</LINK>). Oral/topical non-absorbed antifungal prophylaxis may be compared with placebo or with systemic prophylaxis (<LINK REF="REF-Austin-2007" TYPE="REFERENCE">Austin 2007</LINK>; <LINK REF="REF-Isaacs-2008" TYPE="REFERENCE">Isaacs 2008</LINK>). Any trial should aim to assess long-term outcomes, particularly disability-free survival, as well as the effect on invasive fungal infection.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-09-07 18:04:33 +0100" MODIFIED_BY="[Empty name]">
<P>David Henderson-Smart for his guidance.</P>
<P>Rocio Rodriguez-Lopez for updating the electronic search strategy.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-04-21 14:45:37 +0100" MODIFIED_BY="[Empty name]">
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-09-07 17:59:54 +0100" MODIFIED_BY="[Empty name]">
<P>William McGuire and Jemma Cleminson screened the title and abstract of all studies identified by the search strategy, screened the full text of the report of each study identified as of potential relevance, extracted the data separately, compared data, and resolved differences by consensus. All authors completed the final review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-03-14 11:47:10 +0000" MODIFIED_BY="[Empty name]">
<P>None.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-10-12 14:40:44 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-09-16 15:03:59 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-09-16 15:03:36 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aydemir-2011a" MODIFIED="2013-02-08 17:47:21 +0000" MODIFIED_BY="[Empty name]" NAME="Aydemir 2011a" YEAR="2011">
<REFERENCE MODIFIED="2013-02-08 17:47:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aydemir C, Oguz SS, Dizdar EA, Akar M, Sarikabadayi YU, Saygan S, et al</AU>
<TI>Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>2011</YR>
<VL>96</VL>
<NO>3</NO>
<PG>F164-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="20659937"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aydemir-2011b" MODIFIED="2013-02-08 17:48:07 +0000" MODIFIED_BY="[Empty name]" NAME="Aydemir 2011b" YEAR="">
<REFERENCE MODIFIED="2013-02-08 17:48:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aydemir C, Oguz SS, Dizdar EA, Akar M, Sarikabadayi YU, Saygan S, et al</AU>
<TI>Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>2011</YR>
<VL>96</VL>
<NO>3</NO>
<PG>F164-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="20659937"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mersal-2013" MODIFIED="2015-09-16 15:03:36 +0100" MODIFIED_BY="[Empty name]" NAME="Mersal 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-09-16 15:03:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mersal A, Alzahrani I, Azzouz M, Alsubhi A, Alsawaigh H, Albshri N, et al</AU>
<TI>Oral nystatin versus intravenous fluconazole as neonatal antifungal prophylaxis: non-inferiority trial</TI>
<SO>Journal of Clinical Neonatology</SO>
<YR>2013</YR>
<VL>2</VL>
<NO>2</NO>
<PG>88-92</PG>
<IDENTIFIERS MODIFIED="2015-09-16 15:03:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-09-16 15:03:36 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24049751"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozturk-2006" MODIFIED="2014-08-24 15:19:21 +0100" MODIFIED_BY="[Empty name]" NAME="Ozturk 2006" YEAR="">
<REFERENCE MODIFIED="2014-08-24 15:19:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ozturk MA, Gunes T, Koklu E, Cetin N, Koc N</AU>
<TI>Oral nystatin prophylaxis to prevent invasive candidiasis in Neonatal Intensive Care Unit</TI>
<SO>Mycoses</SO>
<YR>2006</YR>
<VL>49</VL>
<NO>6</NO>
<PG>484-92</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:19:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:19:21 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17022766"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sims-1988" MODIFIED="2014-08-24 15:20:09 +0100" MODIFIED_BY="[Empty name]" NAME="Sims 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-08-24 15:20:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sims ME, Yoo Y, You H, Salminen C, Walther FJ</AU>
<TI>Prophylactic oral nystatin and fungal infections in very-low-birthweight infants</TI>
<SO>American Journal of Perinatology</SO>
<YR>1988</YR>
<VL>5</VL>
<NO>1</NO>
<PG>33-6</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:20:09 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:20:09 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="3276336"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Violaris-2010" MODIFIED="2013-02-08 17:49:37 +0000" MODIFIED_BY="[Empty name]" NAME="Violaris 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-02-08 17:49:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Violaris K, Carbone T, Bateman D, Olawepo O, Doraiswamy B, LaCorte M</AU>
<TI>Comparison of fluconazole and nystatin oral suspensions for prophylaxis of systemic fungal infection in very low birthweight infants</TI>
<SO>American Journal of Perinatology</SO>
<YR>2010</YR>
<VL>27</VL>
<NO>1</NO>
<PG>73-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="19504425"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-14 10:15:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Violaris K, Doraiswamy B, Olawepo O, Gulrajani-LaCorte M</AU>
<TI>Fluconazole versus nystatin prophylaxis for fungal infection in very low birth weight (VLBW) infants</TI>
<SO>Pediatric Research</SO>
<YR>1998</YR>
<VL>44</VL>
<PG>254A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wainer-1992" MODIFIED="2014-08-24 15:30:27 +0100" MODIFIED_BY="[Empty name]" NAME="Wainer 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-08-24 15:30:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wainer S, Cooper PA, Funk E, Bental RY, Sandler DA, Patel J</AU>
<TI>Prophylactic miconazole oral gel for the prevention of neonatal fungal rectal colonization and systemic infection</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1992</YR>
<VL>11</VL>
<NO>9</NO>
<PG>713-6</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:30:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:30:27 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1448310"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-09-16 15:03:59 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Damjanovic-1993" MODIFIED="2014-08-24 15:32:00 +0100" MODIFIED_BY="[Empty name]" NAME="Damjanovic 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-08-24 15:32:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Damjanovic V, Connolly CM, van Saene HK, Cooke RW, Corkill JE, van Belkum A, et al</AU>
<TI>Selective decontamination with nystatin for control of a Candida outbreak in a neonatal intensive care unit</TI>
<SO>Journal of Hospital Infection</SO>
<YR>1993</YR>
<VL>24</VL>
<NO>4</NO>
<PG>245-59</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:32:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:32:00 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8104984"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Demirel-2013" MODIFIED="2015-09-16 15:03:59 +0100" MODIFIED_BY="[Empty name]" NAME="Demirel 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-09-16 15:03:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Demirel G, Celik IH, Erdeve O, Saygan S, Dilmen U, Canpolat FE</AU>
<TI>Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants</TI>
<SO>European Journal of Paediatrics</SO>
<YR>2013</YR>
<VL>172</VL>
<NO>10</NO>
<PG>1321-6</PG>
<IDENTIFIERS MODIFIED="2015-09-16 15:03:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-09-16 15:03:59 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23703468"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-1960" MODIFIED="2014-08-24 15:32:42 +0100" MODIFIED_BY="[Empty name]" NAME="Harris 1960" YEAR="1960">
<REFERENCE MODIFIED="2014-08-24 15:32:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harris LJ</AU>
<TI>Further observations on a simple procedure to eliminate thrush from hospital nurseries</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1960</YR>
<VL>80</VL>
<PG>30-1</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:32:42 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:32:42 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14399978"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herruzo_x002d_Cabrera-1994" MODIFIED="2014-08-24 15:33:33 +0100" MODIFIED_BY="[Empty name]" NAME="Herruzo-Cabrera 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-08-24 15:33:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herruzo-Cabrera R, Garcia Gonzalez JI, Garcia-Magan P, del Rey-Calero J</AU>
<TI>Nosocomial infection in a neonatal intensive care unit and its prevention with selective intestinal decolonization. A multivariant evaluation of infection reduction</TI>
<SO>European Journal of Epidemiology</SO>
<YR>1994</YR>
<VL>10</VL>
<NO>5</NO>
<PG>573-80</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:33:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:33:33 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7859857"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oncel-2015" MODIFIED="2015-09-03 17:59:51 +0100" MODIFIED_BY="[Empty name]" NAME="Oncel 2015" YEAR="2015">
<REFERENCE MODIFIED="2015-09-03 17:59:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oncel MY, Arayici S, Sari FN, Simsek GK, Yurttutan S, Erdeve O, et al</AU>
<TI>Comparison of Lactobacillus reuteri and nystatin prophylaxis on Candida colonization and infection in very low birth weight infants</TI>
<SO>The Journal of Maternal-Fetal &amp; Neonatal Medicine</SO>
<YR>2015</YR>
<VL>28</VL>
<PG>1790-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="25245226"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-09-03 17:58:05 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2015-04-27 16:47:33 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-10-12 14:40:44 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-10-12 14:40:44 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adams_x002d_Chapman-2013" MODIFIED="2014-08-24 15:35:28 +0100" MODIFIED_BY="[Empty name]" NAME="Adams-Chapman 2013" TYPE="JOURNAL_ARTICLE">
<AU>Adams-Chapman I, Bann CM, Das A, Goldberg RN, Stoll BJ, Walsh MC</AU>
<TI>Neurodevelopmental outcome of extremely low birth weight infants with Candida infection</TI>
<SO>The Journal of Pediatrics</SO>
<YR>2013</YR>
<VL>163</VL>
<NO>4</NO>
<PG>961-7</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:35:15 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:35:13 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23726546"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Aliaga-2014" MODIFIED="2014-08-24 15:39:08 +0100" MODIFIED_BY="[Empty name]" NAME="Aliaga 2014" TYPE="JOURNAL_ARTICLE">
<AU>Aliaga S, Clark RH, Laughon M, Walsh TJ, Hope WW, Benjamin DK, et al</AU>
<TI>Changes in the incidence of candidiasis in neonatal intensive care units</TI>
<SO>Pediatrics</SO>
<YR>2014</YR>
<VL>133</VL>
<NO>2</NO>
<PG>236-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="24446441"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ascher-2012" MODIFIED="2014-08-24 15:57:05 +0100" MODIFIED_BY="[Empty name]" NAME="Ascher 2012" TYPE="JOURNAL_ARTICLE">
<AU>Ascher SB, Smith PB, Watt K, Benjamin DK, Cohen-Wolkowiez M, Clark RH, et al</AU>
<TI>Antifungal therapy and outcomes in infants with invasive Candida infections</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>5</NO>
<PG>439-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="22189522"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Austin-2007" MODIFIED="2014-08-24 15:43:11 +0100" MODIFIED_BY="[Empty name]" NAME="Austin 2007" TYPE="COCHRANE_REVIEW">
<AU>Clerihew L, Austin N, McGuire W</AU>
<TI>Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-02-08 17:53:02 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-02-08 17:53:02 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003850.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Barton-2014" MODIFIED="2014-07-31 14:37:31 +0100" MODIFIED_BY="[Empty name]" NAME="Barton 2014" TYPE="JOURNAL_ARTICLE">
<AU>Barton M, O'Brien K, Robinson JL, Davies DH, Simpson K, Asztalos E, et al</AU>
<TI>Invasive candidiasis in low birth weight preterm infants: risk factors, clinical course and outcome in a prospective multicenter study of cases and their matched controls</TI>
<SO>BMC Infectious Diseases</SO>
<YR>2014</YR>
<VL>14</VL>
<PG>327</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="24924877"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Benjamin-2003" MODIFIED="2014-08-24 15:45:27 +0100" MODIFIED_BY="[Empty name]" NAME="Benjamin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Benjamin DK Jr, Poole C, Steibach WJ, Rowen JL, Walsh TJ</AU>
<TI>Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques</TI>
<SO>Pediatrics</SO>
<YR>2003</YR>
<VL>112</VL>
<NO>3 Pt 1</NO>
<PG>634-40</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:45:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:45:27 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12949295"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Benjamin-2006" MODIFIED="2014-08-24 15:46:23 +0100" MODIFIED_BY="[Empty name]" NAME="Benjamin 2006" TYPE="JOURNAL_ARTICLE">
<AU>Benjamin DK Jr, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, et al</AU>
<TI>Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months</TI>
<SO>Pediatrics</SO>
<YR>2006</YR>
<VL>117</VL>
<NO>1</NO>
<PG>84-92</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:46:23 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:46:23 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16396864"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brecht-2009" MODIFIED="2015-10-12 14:40:44 +0100" MODIFIED_BY="[Empty name]" NAME="Brecht 2009" TYPE="JOURNAL_ARTICLE">
<AU>Brecht M, Clerihew L, McGuire W</AU>
<TI>Prevention and treatment of invasive fungal infection in very low birthweight infants</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>2009</YR>
<VL>94</VL>
<NO>1</NO>
<PG>F65-9</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:47:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:47:12 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18838467"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brion-2007" MODIFIED="2014-08-24 15:47:50 +0100" MODIFIED_BY="[Empty name]" NAME="Brion 2007" TYPE="JOURNAL_ARTICLE">
<AU>Brion LP, Uko SE, Goldman DL</AU>
<TI>Risk of resistance associated with fluconazole prophylaxis: systematic review</TI>
<SO>Journal of Infection</SO>
<YR>2007</YR>
<VL>54</VL>
<NO>6</NO>
<PG>521-9</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:47:50 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:47:50 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17239952"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Burwell-2006" MODIFIED="2014-08-24 15:48:41 +0100" MODIFIED_BY="[Empty name]" NAME="Burwell 2006" TYPE="JOURNAL_ARTICLE">
<AU>Burwell LA, Kaufman D, Blakely J, Stoll BJ, Fridkin SK</AU>
<TI>Antifungal prophylaxis to prevent neonatal candidiasis: a survey of perinatal physician practices</TI>
<SO>Pediatrics</SO>
<YR>2006</YR>
<VL>118</VL>
<NO>4</NO>
<PG>e1019-26</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:48:41 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:48:41 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16982807"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clerihew-2006" MODIFIED="2014-08-24 15:49:40 +0100" MODIFIED_BY="[Empty name]" NAME="Clerihew 2006" TYPE="JOURNAL_ARTICLE">
<AU>Clerihew L, Lamagni TL, Brocklehurst P, McGuire W</AU>
<TI>Invasive fungal infection in very low birthweight infants: national prospective surveillance study</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>2006</YR>
<VL>91</VL>
<NO>3</NO>
<PG>F188-92</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:49:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:49:40 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16332924"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clerihew-2008" MODIFIED="2013-02-08 18:02:16 +0000" MODIFIED_BY="[Empty name]" NAME="Clerihew 2008" TYPE="JOURNAL_ARTICLE">
<AU>Clerihew L, McGuire W</AU>
<TI>Antifungal prophylaxis for very low birthweight infants: UK national survey</TI>
<SO>Archives of Disease in Childhood Fetal and Neonatal Edition</SO>
<YR>2008</YR>
<VL>93</VL>
<NO>3</NO>
<PG>F238-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cotten-2006" MODIFIED="2014-08-24 15:50:39 +0100" MODIFIED_BY="[Empty name]" NAME="Cotten 2006" TYPE="JOURNAL_ARTICLE">
<AU>Cotten CM, McDonald S, Stoll B, Goldberg RN, Poole K, Benjamin DK Jr; National Institute for Child Health and Human Development Neonatal Research Network</AU>
<TI>The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants</TI>
<SO>Pediatrics</SO>
<YR>2006</YR>
<VL>118</VL>
<NO>2</NO>
<PG>717-22</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:50:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:50:39 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16882828"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ernst-1983" MODIFIED="2013-02-08 18:03:21 +0000" MODIFIED_BY="[Empty name]" NAME="Ernst 1983" TYPE="JOURNAL_ARTICLE">
<AU>Ernst JA, Williams JM, Glick MR, Lemons JA</AU>
<TI>Osmolality of substances used in the intensive care nursery</TI>
<SO>Pediatrics</SO>
<YR>1983</YR>
<VL>72</VL>
<NO>3</NO>
<PG>347-52</PG>
<IDENTIFIERS MODIFIED="2012-03-15 12:16:37 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="6889039"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Faix-1989" MODIFIED="2014-08-24 15:51:19 +0100" MODIFIED_BY="[Empty name]" NAME="Faix 1989" TYPE="JOURNAL_ARTICLE">
<AU>Faix RG, Kovarik SM, Shaw TR, Johnson RV</AU>
<TI>Mucocutaneous and invasive candidiasis among very low birth weight (&lt;1,500 grams) infants in intensive care nurseries: a prospective study</TI>
<SO>Pediatrics</SO>
<YR>1989</YR>
<VL>83</VL>
<NO>1</NO>
<PG>101-7</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:51:19 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:51:19 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2909957"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Frattarelli-2004" MODIFIED="2014-08-24 15:52:03 +0100" MODIFIED_BY="[Empty name]" NAME="Frattarelli 2004" TYPE="JOURNAL_ARTICLE">
<AU>Frattarelli DA, Reed MD, Giacoia GP, Aranda JV</AU>
<TI>Antifungals in systemic neonatal candidiasis</TI>
<SO>Drugs</SO>
<YR>2004</YR>
<VL>64</VL>
<NO>9</NO>
<PG>949-68</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:52:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:52:03 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15101785"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Friedman-2000" MODIFIED="2014-08-24 15:52:55 +0100" MODIFIED_BY="[Empty name]" NAME="Friedman 2000" TYPE="JOURNAL_ARTICLE">
<AU>Friedman S, Richardson SE, Jacobs SE, O'Brien K</AU>
<TI>Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>6</NO>
<PG>499-504</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:52:55 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:52:55 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10877162"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ganesan-2008" MODIFIED="2014-08-24 15:53:58 +0100" MODIFIED_BY="[Empty name]" NAME="Ganesan 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ganesan K, Harigopal S, Neal T, Yoxall CW</AU>
<TI>Prophylactic oral nystatin for preterm babies under 33 weeks' gestation decreases fungal colonisation and invasive fungaemia</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>2009</YR>
<VL>94</VL>
<NO>4</NO>
<PG>F275 - 8</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:53:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:53:58 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19036756"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-10-12 12:19:40 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>
<I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horbar-2002" MODIFIED="2014-08-24 15:54:53 +0100" MODIFIED_BY="[Empty name]" NAME="Horbar 2002" TYPE="JOURNAL_ARTICLE">
<AU>Horbar JD, Badger GJ, Carpenter JH, Fanaroff AA, Kilpatrick S, LaCorte M, et al; Members of the Vermont Oxford Network</AU>
<TI>Trends in mortality and morbidity for very low birth weight infants, 1991&#8211;1999</TI>
<SO>Pediatrics</SO>
<YR>2002</YR>
<VL>110</VL>
<NO>1 Pt 1</NO>
<PG>143-51</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:54:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:54:53 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12093960"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Howell-2009" MODIFIED="2014-08-24 15:55:53 +0100" MODIFIED_BY="[Empty name]" NAME="Howell 2009" TYPE="JOURNAL_ARTICLE">
<AU>Howell AJ, Isaacs D, Halliday R; Australasian Study Group for Neonatal Infections</AU>
<TI>Oral nystatin prophylaxis and neonatal fungal infections</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>2009</YR>
<VL>94</VL>
<NO>6</NO>
<PG>F429-33</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:55:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:55:36 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19321509"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Huang-1998" MODIFIED="2014-08-24 15:56:47 +0100" MODIFIED_BY="[Empty name]" NAME="Huang 1998" TYPE="JOURNAL_ARTICLE">
<AU>Huang YC, Li CC, Lin TY, Lien RI, Chou YH, Wu JL, et al</AU>
<TI>Association of fungal colonization and invasive disease in very low birth weight infants</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>9</NO>
<PG>819-22</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:56:47 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:56:47 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9779769"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Isaacs-2008" MODIFIED="2014-08-24 15:58:00 +0100" MODIFIED_BY="[Empty name]" NAME="Isaacs 2008" TYPE="JOURNAL_ARTICLE">
<AU>Isaacs D</AU>
<TI>Fungal prophylaxis in very low birth weight neonates: nystatin, fluconazole or nothing?</TI>
<SO>Current Opinion in Infectious Diseases</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>3</NO>
<PG>246-50</PG>
<IDENTIFIERS MODIFIED="2014-08-24 15:58:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 15:58:00 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18448968"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kaguelidou-2012" MODIFIED="2013-02-08 18:19:21 +0000" MODIFIED_BY="[Empty name]" NAME="Kaguelidou 2012" TYPE="JOURNAL_ARTICLE">
<AU>Kaguelidou F, Pandolfini C, Manzoni P, Choonara I, Bonati M, Jacqz-Aigrain E</AU>
<TI>European survey on the use of prophylactic fluconazole in neonatal intensive care units</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2012</YR>
<VL>171</VL>
<NO>3</NO>
<PG>439-45</PG>
<IDENTIFIERS MODIFIED="2012-03-27 17:02:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21912893"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Karlowicz-2002" MODIFIED="2013-02-08 18:26:58 +0000" MODIFIED_BY="[Empty name]" NAME="Karlowicz 2002" TYPE="JOURNAL_ARTICLE">
<AU>Karlowicz MG, Rowen JL, Barnes-Eley ML, Burke BL, Lawson ML, Bendel CM, et al</AU>
<TI>The role of birth weight and gestational age in distinguishing extremely low birth weight infants at high risk of developing candidemia from infants at low risk: a multicenter study</TI>
<SO>Pediatric Research</SO>
<YR>2002</YR>
<VL>51</VL>
<PG>301A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kossoff-1998" MODIFIED="2014-08-24 16:00:24 +0100" MODIFIED_BY="[Empty name]" NAME="Kossoff 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kossoff EH, Buescher ES, Karlowicz MG</AU>
<TI>Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>6</NO>
<PG>504-8</PG>
<IDENTIFIERS MODIFIED="2014-08-24 16:00:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 16:00:24 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9655543"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lee-1998" MODIFIED="2014-08-24 16:02:15 +0100" MODIFIED_BY="[Empty name]" NAME="Lee 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lee BE, Cheung PY, Robinson JL, Evanochko C, Robertson CM</AU>
<TI>Comparative study of mortality and morbidity in premature infants (birth weight &lt; 1,250g) with candidemia or candidal meningitis</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>3</NO>
<PG>559-65</PG>
<IDENTIFIERS MODIFIED="2014-08-24 16:02:15 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 16:02:15 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9770157"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Makhoul-2002" MODIFIED="2013-02-08 18:20:44 +0000" MODIFIED_BY="[Empty name]" NAME="Makhoul 2002" TYPE="JOURNAL_ARTICLE">
<AU>Makhoul IR, Sujov P, Smolkin T, Lusky A, Reichman B</AU>
<TI>Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: a national survey</TI>
<SO>Pediatrics</SO>
<YR>2002</YR>
<VL>109</VL>
<NO>1</NO>
<PG>34-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manzoni-2006" MODIFIED="2013-02-08 18:27:13 +0000" MODIFIED_BY="[Empty name]" NAME="Manzoni 2006" TYPE="JOURNAL_ARTICLE">
<AU>Manzoni P, Farina D, Leonessa M, d'Oulx EA, Galletto P, Mostert M, et al</AU>
<TI>Risk factors for progression to invasive fungal infection in preterm neonates with fungal colonization</TI>
<SO>Pediatrics</SO>
<YR>2006</YR>
<VL>118</VL>
<NO>6</NO>
<PG>2359-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Grady-2008" MODIFIED="2013-02-08 18:21:39 +0000" MODIFIED_BY="[Empty name]" NAME="O'Grady 2008" TYPE="JOURNAL_ARTICLE">
<AU>O'Grady MJ, Dempsey EM</AU>
<TI>Antifungal prophylaxis for the prevention of neonatal candidiasis?</TI>
<SO>Acta Paediatrica</SO>
<YR>2008</YR>
<VL>97</VL>
<NO>4</NO>
<PG>430-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18363952"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oeser-2013" MODIFIED="2014-07-31 14:42:40 +0100" MODIFIED_BY="[Empty name]" NAME="Oeser 2013" TYPE="JOURNAL_ARTICLE">
<AU>Oeser C, Lamagni T, Heath PT, Sharland M, Ladhani S</AU>
<TI>The epidemiology of neonatal and pediatric candidemia in England and Wales, 2000-2009</TI>
<SO>The Pediatric Infectious Disease Journal</SO>
<YR>2013</YR>
<VL>32</VL>
<PG>23-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="23241987"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oeser-2014" MODIFIED="2015-09-03 18:12:12 +0100" MODIFIED_BY="[Empty name]" NAME="Oeser 2014" TYPE="JOURNAL_ARTICLE">
<AU>Oeser C, Vergnano S, Naidoo R, Anthony M, Chang J, Chow P, et al</AU>
<TI>Neonatal invasive fungal infection in England 2004-2010</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>2014</YR>
<VL>20</VL>
<PG>936-41</PG>
<IDENTIFIERS MODIFIED="2014-08-24 16:12:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 16:12:00 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24479862"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pappu_x002d_Katikaneni-1990" MODIFIED="2014-08-24 16:03:03 +0100" MODIFIED_BY="[Empty name]" NAME="Pappu-Katikaneni 1990" TYPE="JOURNAL_ARTICLE">
<AU>Pappu-Katikaneni LD, Rao KP, Banister E</AU>
<TI>Gastrointestinal colonization with yeast species and Candida septicemia in very low birth weight infants</TI>
<SO>Mycoses</SO>
<YR>1990</YR>
<VL>33</VL>
<NO>1</NO>
<PG>20-3</PG>
<IDENTIFIERS MODIFIED="2014-08-24 16:03:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 16:03:03 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2342516"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Radmacher-2012" MODIFIED="2013-02-08 18:22:40 +0000" MODIFIED_BY="[Empty name]" NAME="Radmacher 2012" TYPE="JOURNAL_ARTICLE">
<AU>Radmacher PG, Adamkin MD, Lewis ST, Adamkin DH</AU>
<TI>Milk as a vehicle for oral medications: hidden osmoles</TI>
<SO>Journal of Perinatology</SO>
<YR>2012</YR>
<VL>32</VL>
<NO>3</NO>
<PG>227-9</PG>
<IDENTIFIERS MODIFIED="2012-03-15 12:16:37 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21701446"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Robinson-2009" MODIFIED="2014-07-31 14:36:42 +0100" MODIFIED_BY="[Empty name]" NAME="Robinson 2009" TYPE="JOURNAL_ARTICLE">
<AU>Robinson JL, Davies HD, Barton M, O'Brien K, Simpson K, Asztalos E, et al</AU>
<TI>Characteristics and outcome of infants with candiduria in neonatal intensive care - a Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study</TI>
<SO>BMC Infectious Diseases</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>183</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="19930662"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rowen-1994" MODIFIED="2014-08-24 16:05:15 +0100" MODIFIED_BY="[Empty name]" NAME="Rowen 1994" TYPE="JOURNAL_ARTICLE">
<AU>Rowen JL, Rench MA, Kozinetz CA, Adams JM, Baker CJ</AU>
<TI>Endotracheal colonization with candida enhances risk of systemic candidiasis in very low birth weight neonates</TI>
<SO>Journal of Pediatrics</SO>
<YR>1994</YR>
<VL>124</VL>
<NO>5 Pt 1</NO>
<PG>789-94</PG>
<IDENTIFIERS MODIFIED="2014-08-24 16:05:15 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 16:05:15 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8176570"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Saiman-2000" MODIFIED="2014-08-24 16:06:26 +0100" MODIFIED_BY="[Empty name]" NAME="Saiman 2000" TYPE="JOURNAL_ARTICLE">
<AU>Saiman L, Ludington E, Pfaller M, Rangel-Frausto S, Wiblin RT, Dawson J, et al</AU>
<TI>Risk factors for candidemia in Neonatal Intensive Care Unit patients. The national epidemiology of mycosis survey study group</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>4</NO>
<PG>319-24</PG>
<IDENTIFIERS MODIFIED="2014-08-24 16:06:26 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 16:06:26 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10783022"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shane-2013" MODIFIED="2014-08-24 16:13:46 +0100" MODIFIED_BY="[Empty name]" NAME="Shane 2013" TYPE="JOURNAL_ARTICLE">
<AU>Shane AL, Stoll BJ</AU>
<TI>Recent developments and current issues in the epidemiology, diagnosis, and management of bacterial and fungal neonatal sepsis</TI>
<SO>American Journal of Perinatology</SO>
<YR>2013</YR>
<VL>30</VL>
<NO>2</NO>
<PG>131-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="23297182"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stoll-2002" MODIFIED="2014-08-24 16:14:26 +0100" MODIFIED_BY="[Empty name]" NAME="Stoll 2002" TYPE="JOURNAL_ARTICLE">
<AU>Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al</AU>
<TI>Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network</TI>
<SO>Pediatrics</SO>
<YR>2002</YR>
<VL>110</VL>
<NO>2 Pt 1</NO>
<PG>285-91</PG>
<IDENTIFIERS MODIFIED="2014-08-24 16:14:26 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-24 16:14:26 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12165580"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vergnano-2011" MODIFIED="2014-07-31 14:41:28 +0100" MODIFIED_BY="[Empty name]" NAME="Vergnano 2011" TYPE="JOURNAL_ARTICLE">
<AU>Vergnano S, Menson E, Kennea N, Embleton N, Russell AB, Watts T, et al</AU>
<TI>Neonatal infections in England: the NeonIN surveillance network</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>2011</YR>
<VL>96</VL>
<NO>1</NO>
<PG>F9-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="20876594"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wynn-2012" MODIFIED="2014-07-31 14:37:00 +0100" MODIFIED_BY="[Empty name]" NAME="Wynn 2012" TYPE="JOURNAL_ARTICLE">
<AU>Wynn JL, Tan S, Gantz MG, Das A, Goldberg RN, Adams-Chapman I, et al</AU>
<TI>Outcomes following candiduria in extremely low birth weight infants</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2012</YR>
<VL>54</VL>
<NO>3</NO>
<PG>331-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="22144537"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-08-04 17:11:30 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Austin-2004" MODIFIED="2012-09-12 18:17:22 +0100" MODIFIED_BY="[Empty name]" NAME="Austin 2004" TYPE="COCHRANE_REVIEW">
<AU>Austin NC, Darlow B</AU>
<TI>Prophylactic oral antifungal agents to prevent systemic candida infection in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-09-12 18:17:22 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-09-12 18:17:22 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003478.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Austin-2009" MODIFIED="2012-09-12 17:58:12 +0100" MODIFIED_BY="[Empty name]" NAME="Austin 2009" TYPE="COCHRANE_REVIEW">
<AU>Austin N, Darlow BA, McGuire W</AU>
<TI>Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-09-12 17:58:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-09-12 17:58:12 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003478.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Austin-2013" MODIFIED="2014-08-04 17:11:30 +0100" MODIFIED_BY="[Empty name]" NAME="Austin 2013" TYPE="COCHRANE_REVIEW">
<AU>Austin N, Darlow BA, McGuire W</AU>
<TI>Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003478.pub4"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-10-15 12:12:21 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-10-15 12:12:21 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-10-12 14:28:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aydemir-2011a">
<CHAR_METHODS MODIFIED="2012-09-05 19:56:05 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-09-05 19:56:07 +0100" MODIFIED_BY="[Empty name]">
<P>185 VLBW infants</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-12 14:27:38 +0100" MODIFIED_BY="[Empty name]">
<P>Oral nystatin 100,000 U/ml 8 hourly (N = 94) versus normal saline placebo* (N = 91) every third day versus until the 30th day after birth (or 45th day in ELBW infants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-05 19:56:26 +0100" MODIFIED_BY="[Empty name]">
<P>Fungal colonisation and invasive infection</P>
<P>Death prior to hospital discharge</P>
<P>Emergence of fungi with native azole resistance<BR/>Adverse drug reactions<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-10-12 14:28:47 +0100" MODIFIED_BY="[Empty name]">
<P>Setting: Zekai Tahir Burak Maternity Hospital, Ankara, Turkey; 2008 to 2009</P>
<P>*Report states placebo-controlled but unclear how this was achieved</P>
<P>The same infants form the oral nystatin group in both <LINK REF="STD-Aydemir-2011a" TYPE="STUDY">Aydemir 2011a</LINK> and <LINK REF="STD-Aydemir-2011b" TYPE="STUDY">Aydemir 2011b</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-12 14:29:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aydemir-2011b">
<CHAR_METHODS MODIFIED="2012-09-05 19:56:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-14 10:16:25 +0000" MODIFIED_BY="[Empty name]">
<P>187 VLBW infants.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-12 14:29:21 +0100" MODIFIED_BY="[Empty name]">
<P>Oral nystatin 100,000 U/ml 8 hourly (N = 94) versus fluconazole 3 mg/kg (N = 93) every third day versus until the 30th day after birth (or 45th day in ELBW infants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-05 19:57:11 +0100" MODIFIED_BY="[Empty name]">
<P>Fungal colonisation and invasive infection</P>
<P>Death prior to hospital discharge</P>
<P>Emergence of fungi with native azole resistance<BR/>Adverse drug reactions<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-10-12 14:29:17 +0100" MODIFIED_BY="[Empty name]">
<P>Setting: Zekai Tahir Burak Maternity Hospital, Ankara, Turkey; 2008 to 2009</P>
<P>The same infants form the oral nystatin group in both <LINK REF="STD-Aydemir-2011a" TYPE="STUDY">Aydemir 2011a</LINK> and <LINK REF="STD-Aydemir-2011b" TYPE="STUDY">Aydemir 2011b</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-15 12:12:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mersal-2013">
<CHAR_METHODS MODIFIED="2014-07-24 13:21:04 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-15 12:12:05 +0100" MODIFIED_BY="[Empty name]">
<P>59 preterm infants &lt; 30 weeks, birth weight &lt; 1200 grams.</P>
<P>Exclusion criteria: severe congenital anomalies, severe sepsis, intraventricular haemorrhage, persistent pulmonary hypertension, coagulopathy. </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-12 14:31:44 +0100" MODIFIED_BY="[Empty name]">
<P>Oral nystatin 1 ml (100,000 IU) every 8 h for first six weeks of life (N = 24) or intravenous fluconazole 6 mg/kg every 72 hours at end of first week of life, then every 48 hours from second week to sixth week of life (N = 35). Interventions commenced at one week of age.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-24 15:04:21 +0100" MODIFIED_BY="[Empty name]">
<P>Invasive fungal infection</P>
<P>Mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-10-15 12:12:21 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Jeddah, Saudi Arabia. Participants enrolled February 2011 to February 2012.</P>
<P>60 infants were enrolled in the study. 3 were withdrawn from analysis (2 severe bacterial sepsis in fluconazole group, 1 Edwards syndrome). 57 were included in final analysis (24 in nystatin group, 33 in fluconazole group). The allocation group for the infant with Edwards syndrome is unknown.</P>
<P>It is unclear as to whether the two infants with bacterial sepsis were withdrawn from analysis from the initial N = 35 (see above) or the N = 33 as the report quotes "2/33...in fluconazole group died because of bacterial sepsis...excluded from the study". The study author has been contacted and clarification if awaited.</P>
<P>We have therefore assumed that there were a total of two deaths of N = 35 in the fluconazole group, and no deaths of N = 24 in the nystatin group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-12 14:32:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ozturk-2006">
<CHAR_METHODS MODIFIED="2012-03-14 10:43:51 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-08 17:45:27 +0000" MODIFIED_BY="[Empty name]">
<P>938 VLBW infants with subgroup report for ELBW infants (N = 349)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-08 17:45:31 +0000" MODIFIED_BY="[Empty name]">
<P>Nystatin 100000 IU orally, 8 hourly (N = 475) versus no drug (N = 463)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-05 19:57:35 +0100" MODIFIED_BY="[Empty name]">
<P>Fungal colonisation and invasive fungal infection</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-10-12 14:32:18 +0100" MODIFIED_BY="[Empty name]">
<P>Setting: Division of Neonatology, Erciyes University Hospital, Turkey, 2002 to 2005</P>
<P>25% of control VLBW infants received nystatin (100,000 IU orally, 8 hourly) to treat oral fungal colonisation detected at trial entry or during the trial period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-12 14:34:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sims-1988">
<CHAR_METHODS MODIFIED="2012-03-14 11:21:26 +0000" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised controlled trial; odd or even hospital number allocation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-08 17:45:36 +0000" MODIFIED_BY="[Empty name]">
<P>67 infants of birth weight &lt; 1250 grams<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-12 14:32:53 +0100" MODIFIED_BY="[Empty name]">
<P>Nystatin 1 ml orally, 8 hourly (N = 33) versus no drug (N = 34)</P>
<P>Treatment from inclusion until one week after endotracheal extubation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-05 19:58:08 +0100" MODIFIED_BY="[Empty name]">
<P>Fungal colonisation and invasive fungal infection</P>
<P>Duration of mechanical ventilation and duration of intensive care admission</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-10-12 14:34:30 +0100" MODIFIED_BY="[Empty name]">
<P>Setting: Los Angeles County+University of Southern California Medical Centre, 1985 to 1986</P>
<P>The study took place during a period of overcrowding in the intensive care unit; 222 infants with a birthweight &lt; 1250 grams were born during a 12-month period; 55 died within 48 hours, 88 relatively healthy infants were transferred elsewhere and 67 of the remaining 88 infants were recruited to the study.</P>
<P>One infant in the control group had <I>Candida albicans</I> pneumonia supported by postmortem evidence. All the other affected infants had positive urine and blood cultures</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-05 20:19:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Violaris-2010">
<CHAR_METHODS MODIFIED="2012-03-14 10:15:30 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-04-27 16:49:09 +0100" MODIFIED_BY="[Empty name]">
<P>80 VLBW infants</P>
<P>Haemodynamically unstable infants and infants with severe congenital anomalies or abnormal liver function tests were not eligible to participate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-08 17:45:53 +0000" MODIFIED_BY="[Empty name]">
<P>Nystatin (100,000 units/kg/day) in each side of the mouth (N = 42) versus fluconazole (4 mg/kg) orally (N = 38) beginning on day five after birth</P>
<P>Medications were continued until full oral feedings were attained or systemic fungal infection was diagnosed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-05 19:58:43 +0100" MODIFIED_BY="[Empty name]">
<P>Invasive fungal infection, invasive bacterial infection, biochemical indices related to liver function, mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-10-05 20:19:46 +0100" MODIFIED_BY="[Empty name]">
<P>Setting: Brooklyn Hospital Center, New York; 1997 to 1998</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-12 14:35:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wainer-1992">
<CHAR_METHODS MODIFIED="2012-03-14 10:47:44 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-08 17:45:58 +0000" MODIFIED_BY="[Empty name]">
<P>600 infants of birth weight &lt; 1750 grams.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-12 14:35:38 +0100" MODIFIED_BY="[Empty name]">
<P>Miconazole 0.75 ml orally 3 times daily (N = 302) vs. placebo (N = 298)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-05 19:59:04 +0100" MODIFIED_BY="[Empty name]">
<P>Fungal colonisation and invasive fungal infection. Duration of mechanical ventilation and duration of intensive care admission</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-08 21:08:22 +0100" MODIFIED_BY="[Empty name]">
<P>Setting: Baragwanath Hospital, South Africa from October 1989 to July 1990</P>
<P>Due to limited resources, mechanical ventilation was not offered to infants with birth weight &lt; 1000 grams. This group made up 12% (73/600) of the infants and had a high mortality rate (67%)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ELBW: extremely low birth weight<BR/>VLBW: very low birth weight</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-10-05 20:20:36 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-09-05 19:59:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Damjanovic-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-05 19:59:16 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-03 18:02:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Demirel-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-03 18:02:21 +0100" MODIFIED_BY="[Empty name]">
<P>Trial of nystatin versus probiotic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-05 20:20:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harris-1960">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-05 20:20:36 +0100" MODIFIED_BY="[Empty name]">
<P>The gestational age or birth weight of participants was not reported &#8211; assumed to include term and preterm infants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-05 19:59:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Herruzo_x002d_Cabrera-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-05 19:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>A prospective cohort study but not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-03 18:02:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oncel-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-03 18:02:27 +0100" MODIFIED_BY="[Empty name]">
<P>Trial of nystatin versus probiotic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-09-03 17:58:05 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-04-27 16:47:33 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-10-12 14:29:45 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-03-14 10:22:59 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-07-24 13:22:01 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-14 10:49:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aydemir-2011a">
<DESCRIPTION>
<P>Computer-generated allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-14 10:49:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aydemir-2011b">
<DESCRIPTION>
<P>Computer-generated allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-24 13:22:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mersal-2013">
<DESCRIPTION>
<P>Computer-generated randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-29 15:43:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ozturk-2006">
<DESCRIPTION>
<P>Randomly assigned by "someone not directly involved in the study" using random number tables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-14 10:45:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sims-1988">
<DESCRIPTION>
<P>Quasi-randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-14 10:47:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Violaris-2010">
<DESCRIPTION>
<P>Computerised randomisation and allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-30 14:54:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wainer-1992">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-10-12 14:29:38 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-10-12 14:28:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aydemir-2011a">
<DESCRIPTION>
<P>Report states placebo-controlled but unclear how this was achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-10-12 14:29:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aydemir-2011b">
<DESCRIPTION>
<P>Report states placebo-controlled but unclear how this was achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-07-24 13:21:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mersal-2013">
<DESCRIPTION>
<P>Unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-14 10:32:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ozturk-2006">
<DESCRIPTION>
<P>Unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-14 10:45:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sims-1988">
<DESCRIPTION>
<P>Unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-14 10:21:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Violaris-2010">
<DESCRIPTION>
<P>Unable to blind interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-14 10:50:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wainer-1992">
<DESCRIPTION>
<P>Placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-10-12 14:29:41 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-10-12 14:28:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aydemir-2011a">
<DESCRIPTION>
<P>Report states placebo-controlled but unclear how this was achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-10-12 14:29:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aydemir-2011b">
<DESCRIPTION>
<P>Report states placebo-controlled but unclear how this was achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-24 13:21:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mersal-2013">
<DESCRIPTION>
<P>Unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-14 10:32:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ozturk-2006">
<DESCRIPTION>
<P>Unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-14 10:45:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sims-1988">
<DESCRIPTION>
<P>Unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-14 10:47:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Violaris-2010">
<DESCRIPTION>
<P>Unable to blind interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-14 10:50:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wainer-1992">
<DESCRIPTION>
<P>Placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-10-12 14:29:45 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-10-12 14:28:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aydemir-2011a">
<DESCRIPTION>
<P>Report states placebo-controlled but unclear how this was achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-10-12 14:29:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aydemir-2011b">
<DESCRIPTION>
<P>Report states placebo-controlled but unclear how this was achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-07-24 13:21:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mersal-2013">
<DESCRIPTION>
<P>Unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-14 10:32:53 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ozturk-2006">
<DESCRIPTION>
<P>Unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-14 10:45:48 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sims-1988">
<DESCRIPTION>
<P>Unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-14 10:47:17 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Violaris-2010">
<DESCRIPTION>
<P>Unable to blind interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-14 10:50:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wainer-1992">
<DESCRIPTION>
<P>Placebo-controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-07-24 13:21:58 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-14 10:49:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aydemir-2011a">
<DESCRIPTION>
<P>Complete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-14 10:31:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aydemir-2011b">
<DESCRIPTION>
<P>Complete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-24 13:21:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mersal-2013">
<DESCRIPTION>
<P>See notes above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-14 10:43:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ozturk-2006">
<DESCRIPTION>
<P>Complete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-14 10:45:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sims-1988">
<DESCRIPTION>
<P>Complete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-14 10:47:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Violaris-2010">
<DESCRIPTION>
<P>Complete follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-14 10:50:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wainer-1992">
<DESCRIPTION>
<P>Complete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-03-14 10:23:30 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-03-14 10:21:49 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2012-03-14 18:15:47 +0000" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-10-15 11:54:46 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-10-15 11:54:46 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Oral/topical non-absorbed antifungal prophylaxis vs placebo or nothing</NAME>
<DICH_OUTCOME CHI2="16.00483416329851" CI_END="0.24318756777234152" CI_START="0.13419310062014053" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.18064909009358746" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="255" I2="75.00755109870116" I2_Q="16.320501232953898" ID="CMP-001.01" LOG_CI_END="-0.6140586308214967" LOG_CI_START="-0.8722698123311655" LOG_EFFECT_SIZE="-0.7431642215763311" METHOD="MH" MODIFIED="2015-10-15 11:54:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.003012691806649981" P_Q="0.2743161781666785" P_Z="1.609597619328642E-29" Q="1.1950358388066862" RANDOM="NO" SCALE="23.13" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1086" TOTAL_2="1063" WEIGHT="200.0" Z="11.282045187758934">
<NAME>Incidence of invasive fungal infection</NAME>
<GROUP_LABEL_1>Prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.644572979725096" CI_END="0.27076316621302393" CI_START="0.14170088762126795" DF="3" EFFECT_SIZE="0.19587593263984834" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="203" I2="79.514595583269" ID="CMP-001.01.01" LOG_CI_END="-0.5674104160520838" LOG_CI_START="-0.8486274293022127" LOG_EFFECT_SIZE="-0.7080189226771482" MODIFIED="2015-10-12 20:03:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.002147021034610508" P_Z="5.66218883109661E-23" STUDIES="4" TAU2="0.0" TOTAL_1="904" TOTAL_2="896" WEIGHT="100.0" Z="9.869186595661446">
<NAME>All VLBW infants</NAME>
<DICH_DATA CI_END="0.7485725307468942" CI_START="0.08902882786341974" EFFECT_SIZE="0.2581560283687943" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" LOG_CI_END="-0.1257661135880506" LOG_CI_START="-1.0504693444245974" LOG_EFFECT_SIZE="-0.588117729006324" MODIFIED="2014-07-31 13:44:47 +0100" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.5431752551482028" STUDY_ID="STD-Aydemir-2011a" TOTAL_1="94" TOTAL_2="91" VAR="0.2950393578053152" WEIGHT="7.491279956472959"/>
<DICH_DATA CI_END="0.22416955272660746" CI_START="0.10226167737664293" EFFECT_SIZE="0.1514065866420437" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="171" LOG_CI_END="-0.6494233747061613" LOG_CI_START="-0.9902870879106206" LOG_EFFECT_SIZE="-0.8198552313083909" MODIFIED="2012-03-14 11:51:55 +0000" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.20022503243889214" STUDY_ID="STD-Ozturk-2006" TOTAL_1="475" TOTAL_2="473" VAR="0.040090063615155415" WEIGHT="84.21511107814545"/>
<DICH_DATA CI_END="0.7815993085785111" CI_START="0.04489731905316008" EFFECT_SIZE="0.18732782369146006" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.10701583347642524" LOG_CI_START="-1.3477795911833272" LOG_EFFECT_SIZE="-0.7273977123298762" MODIFIED="2012-03-14 11:52:01 +0000" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.7288307731566899" STUDY_ID="STD-Sims-1988" TOTAL_1="33" TOTAL_2="34" VAR="0.5311942959001783" WEIGHT="5.325255694685525"/>
<DICH_DATA CI_END="3.745976907245161" CI_START="0.4620947343594804" EFFECT_SIZE="1.315673289183223" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.573565095760278" LOG_CI_START="-0.33526898030546887" LOG_EFFECT_SIZE="0.11914805772740457" MODIFIED="2015-10-12 20:03:49 +0100" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.533853635082252" STUDY_ID="STD-Wainer-1992" TOTAL_1="302" TOTAL_2="298" VAR="0.28499970369053435" WEIGHT="2.968353270696058"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.26428547953704634" CI_START="0.05773062462700766" DF="0" EFFECT_SIZE="0.1235207100591716" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="52" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.5779266973683646" LOG_CI_START="-1.238593743547703" LOG_EFFECT_SIZE="-0.9082602204580338" MODIFIED="2009-04-16 19:03:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="7.086278182419992E-8" STUDIES="1" TAU2="0.0" TOTAL_1="182" TOTAL_2="167" WEIGHT="100.0" Z="5.3889696208789895">
<NAME>Only ELBW infants</NAME>
<DICH_DATA CI_END="0.26428547953704634" CI_START="0.05773062462700766" EFFECT_SIZE="0.1235207100591716" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="52" LOG_CI_END="-0.5779266973683646" LOG_CI_START="-1.238593743547703" LOG_EFFECT_SIZE="-0.9082602204580338" MODIFIED="2009-04-16 18:54:43 +0100" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.38807909328036566" STUDY_ID="STD-Ozturk-2006" TOTAL_1="182" TOTAL_2="167" VAR="0.15060538264131076" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1927245571828191" CI_END="1.0562247430570968" CI_START="0.7334706008753948" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8801760033933829" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="181" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.0237563370279699" LOG_CI_START="-0.13461728895562391" LOG_EFFECT_SIZE="-0.055430475963827004" METHOD="MH" MODIFIED="2015-10-15 11:54:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8792950287874723" P_Q="0.5874659070669476" P_Z="0.17007354490200857" Q="0.29431929722051847" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1086" TOTAL_2="1063" WEIGHT="200.0" Z="1.3719675338653734">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8956849335190107" CI_END="1.0450547900354685" CI_START="0.7178830069905443" DF="3" EFFECT_SIZE="0.8661564957561272" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="169" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.019139060194723598" LOG_CI_START="-0.14394632673039442" LOG_EFFECT_SIZE="-0.062403633267835434" MODIFIED="2012-03-14 11:05:47 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8264691234122064" P_Z="0.13363081559103204" STUDIES="4" TAU2="0.0" TOTAL_1="904" TOTAL_2="896" WEIGHT="100.0" Z="1.499936640743443">
<NAME>All VLBW infants</NAME>
<DICH_DATA CI_END="1.670315112011687" CI_START="0.2967722372877393" EFFECT_SIZE="0.7040618955512572" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.22279841036809034" LOG_CI_START="-0.5275767292578636" LOG_EFFECT_SIZE="-0.15238915944488654" MODIFIED="2012-03-14 11:05:00 +0000" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.44077407143313174" STUDY_ID="STD-Aydemir-2011a" TOTAL_1="94" TOTAL_2="91" VAR="0.19428178204773952" WEIGHT="6.578570939365057"/>
<DICH_DATA CI_END="1.523865479624727" CI_START="0.6140591068514916" EFFECT_SIZE="0.9673383458646616" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" LOG_CI_END="0.18294663102247422" LOG_CI_START="-0.21178982341262526" LOG_EFFECT_SIZE="-0.014421596195075536" MODIFIED="2009-04-16 18:48:47 +0100" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.23187014731214023" STUDY_ID="STD-Ozturk-2006" TOTAL_1="475" TOTAL_2="473" VAR="0.05376376521455361" WEIGHT="20.641253545471535"/>
<DICH_DATA CI_END="1.8248516355980742" CI_START="0.18994431328793163" EFFECT_SIZE="0.5887445887445888" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.26122756114301304" LOG_CI_START="-0.7213737041868664" LOG_EFFECT_SIZE="-0.23007307152192677" MODIFIED="2012-03-14 11:05:47 +0000" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.5771848472094795" STUDY_ID="STD-Sims-1988" TOTAL_1="33" TOTAL_2="34" VAR="0.33314234784823016" WEIGHT="4.058073689970347"/>
<DICH_DATA CI_END="1.0731231817719737" CI_START="0.7015416027920958" EFFECT_SIZE="0.8676638501941083" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="116" LOG_CI_END="0.030649576666140137" LOG_CI_START="-0.15394656935793272" LOG_EFFECT_SIZE="-0.06164849634589629" MODIFIED="2012-03-14 11:05:46 +0000" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.1084326899402002" STUDY_ID="STD-Wainer-1992" TOTAL_1="302" TOTAL_2="298" VAR="0.011757648247667592" WEIGHT="68.72210182519308"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2479720787968374" CI_START="0.5097917850899983" DF="0" EFFECT_SIZE="1.0705128205128205" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.35179091272452895" LOG_CI_START="-0.29260716713828566" LOG_EFFECT_SIZE="0.02959187279312167" MODIFIED="2009-04-17 11:50:20 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8571448255212931" STUDIES="1" TAU2="0.0" TOTAL_1="182" TOTAL_2="167" WEIGHT="100.0" Z="0.18000986260529064">
<NAME>Only ELBW infants</NAME>
<DICH_DATA CI_END="2.2479720787968374" CI_START="0.5097917850899983" EFFECT_SIZE="1.0705128205128205" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.35179091272452895" LOG_CI_START="-0.29260716713828566" LOG_EFFECT_SIZE="0.02959187279312167" MODIFIED="2009-04-17 11:50:20 +0100" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.37852262193335745" STUDY_ID="STD-Ozturk-2006" TOTAL_1="182" TOTAL_2="167" VAR="0.14327937531530346" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.493115468101268" CI_START="0.6700538298707719" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2924865831842576" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.396742393224159" LOG_CI_START="-0.17389030613983467" LOG_EFFECT_SIZE="0.11142604354216216" METHOD="MH" MODIFIED="2012-03-19 17:33:28 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.44401274779346844" Q="0.0" RANDOM="NO" SCALE="2.61" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="85" WEIGHT="100.0" Z="0.7654346921437919">
<NAME>Bronchopulmonary dysplasia</NAME>
<GROUP_LABEL_1>Prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4931154681012684" CI_START="0.6700538298707718" EFFECT_SIZE="1.2924865831842576" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.39674239322415905" LOG_CI_START="-0.17389030613983472" LOG_EFFECT_SIZE="0.11142604354216216" MODIFIED="2012-03-19 17:27:28 +0000" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.3351924722838276" STUDY_ID="STD-Aydemir-2011a" TOTAL_1="86" TOTAL_2="85" VAR="0.11235399347574453" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.328885749858622" CI_START="0.4024193858618597" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9680851063829787" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.36714818350118195" LOG_CI_START="-0.395321106058392" LOG_EFFECT_SIZE="-0.014086461278605055" METHOD="MH" MODIFIED="2012-03-19 17:36:38 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9422677861965734" Q="0.0" RANDOM="NO" SCALE="6.28" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="94" TOTAL_2="91" WEIGHT="100.0" Z="0.07241985258614611">
<NAME>Necrotising enterocolitis</NAME>
<GROUP_LABEL_1>Prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.328885749858622" CI_START="0.40241938586185966" EFFECT_SIZE="0.9680851063829787" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.36714818350118195" LOG_CI_START="-0.3953211060583921" LOG_EFFECT_SIZE="-0.014086461278605055" MODIFIED="2012-03-19 17:36:38 +0000" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.447878234971148" STUDY_ID="STD-Aydemir-2011a" TOTAL_1="94" TOTAL_2="91" VAR="0.20059491336087082" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2830393984352004" CI_START="0.3019590475881207" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6224350205198358" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" I2="0.0" I2_Q="100.0" ID="CMP-001.05" LOG_CI_END="0.10823999250921774" LOG_CI_START="-0.5200519531107138" LOG_EFFECT_SIZE="-0.20590598030074808" METHOD="MH" MODIFIED="2012-03-19 17:42:20 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.19891385936665412" Q="2.262362948689196E-32" RANDOM="NO" SCALE="3.5804146565855475" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="91" WEIGHT="100.0" Z="1.2846521697574265">
<NAME>Retinopathy of prematurity</NAME>
<GROUP_LABEL_1>Prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2830393984352004" CI_START="0.3019590475881207" EFFECT_SIZE="0.6224350205198358" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="0.10823999250921774" LOG_CI_START="-0.5200519531107138" LOG_EFFECT_SIZE="-0.20590598030074808" MODIFIED="2012-03-19 17:39:36 +0000" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.3690617989524377" STUDY_ID="STD-Aydemir-2011a" TOTAL_1="86" TOTAL_2="91" VAR="0.13620661144600954" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.48058132569605577" CI_END="3.294048893152981" CI_START="-4.341447508365895" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.523699307606457" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2012-03-19 17:46:31 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.7863992582379269" P_Q="1.0" P_Z="0.7880390320871534" Q="0.0" RANDOM="NO" SCALE="21.18" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="421" TOTAL_2="412" UNITS="" WEIGHT="100.0" Z="0.26885790462373554">
<NAME>Length of stay in NICU (days)</NAME>
<GROUP_LABEL_1>Prophylaxis</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prophylaxis</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="20.521893601984484" CI_START="-12.521893601984484" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="66.0" MEAN_2="62.0" MODIFIED="2012-03-19 17:43:23 +0000" MODIFIED_BY="[Empty name]" ORDER="48" SD_1="34.0" SD_2="35.0" SE="8.429692449609826" STUDY_ID="STD-Sims-1988" TOTAL_1="33" TOTAL_2="34" WEIGHT="5.339430281599985"/>
<CONT_DATA CI_END="4.564055916500684" CI_START="-4.9640559165006755" EFFECT_SIZE="-0.19999999999999574" ESTIMABLE="YES" MEAN_1="46.7" MEAN_2="46.9" MODIFIED="2012-03-19 17:43:25 +0000" MODIFIED_BY="[Empty name]" ORDER="49" SD_1="21.7" SD_2="36.0" SE="2.430685438140162" STUDY_ID="STD-Wainer-1992" TOTAL_1="302" TOTAL_2="298" WEIGHT="64.21860419430784"/>
<CONT_DATA CI_END="4.91943981587258" CI_START="-8.919439815872579" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="47.0" MODIFIED="2012-03-19 17:43:21 +0000" MODIFIED_BY="[Empty name]" ORDER="19" SD_1="20.0" SD_2="25.0" SE="3.5303913084384395" STUDY_ID="STD-Aydemir-2011a" TOTAL_1="86" TOTAL_2="80" WEIGHT="30.441965524092176"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-07-31 15:01:01 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Oral/topical non-absorbed prophylaxis vs. systemic antifungal prophylaxis</NAME>
<DICH_OUTCOME CHI2="0.4426988951198597" CI_END="5.38856603556827" CI_START="0.6641778725548142" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.891815616180621" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.7314732093991572" LOG_CI_START="-0.1777155972522667" LOG_EFFECT_SIZE="0.2768788060734452" METHOD="MH" MODIFIED="2014-07-31 15:01:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5058227063469793" P_Q="1.0" P_Z="0.2325754363734286" Q="0.0" RANDOM="NO" SCALE="13.214308956877186" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="160" TOTAL_2="166" WEIGHT="100.0" Z="1.1937509217366755">
<NAME>Incidence of invasive fungal infection</NAME>
<GROUP_LABEL_1>Oral/topical non-absorbed</GROUP_LABEL_1>
<GROUP_LABEL_2>Systemic prophylaxis</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral/topical</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours systemic</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.732954046239883" CI_START="0.30353529816628" EFFECT_SIZE="1.3191489361702127" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7583784606052304" LOG_CI_START="-0.5177907974801574" LOG_EFFECT_SIZE="0.12029383156253638" MODIFIED="2012-03-14 11:09:28 +0000" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.7496281393390658" STUDY_ID="STD-Aydemir-2011b" TOTAL_1="94" TOTAL_2="93" VAR="0.5619423472889499" WEIGHT="58.95264973345877"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-07-24 14:32:28 +0100" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="0.0" STUDY_ID="STD-Mersal-2013" TOTAL_1="24" TOTAL_2="35" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.647953684614102" CI_START="0.5824931939573508" EFFECT_SIZE="2.7142857142857144" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1020202665894474" LOG_CI_START="-0.2347091447123031" LOG_EFFECT_SIZE="0.43365556093857216" MODIFIED="2012-03-14 11:09:57 +0000" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.7852014731159505" STUDY_ID="STD-Violaris-2010" TOTAL_1="42" TOTAL_2="38" VAR="0.6165413533834586" WEIGHT="41.04735026654124"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7355706919214913" CI_END="3.003364017484342" CI_START="0.641010638154224" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3875115442608295" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" I2="46.46065715406804" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.4776079732924943" LOG_CI_START="-0.19313476290966997" LOG_EFFECT_SIZE="0.14223660519141218" METHOD="MH" MODIFIED="2014-07-24 15:08:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.15446546688344076" P_Q="1.0" P_Z="0.4058304454860897" Q="0.0" RANDOM="NO" SCALE="191.41035960398136" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="160" TOTAL_2="166" WEIGHT="100.0" Z="0.8312534997751683">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Oral/topical non-absorbed</GROUP_LABEL_1>
<GROUP_LABEL_2>Systemic prophylaxis</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral/topical</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours systemic</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5254613540126942" CI_START="0.3875872327571637" EFFECT_SIZE="0.9893617021276596" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.4023407270881423" LOG_CI_START="-0.4116305371796693" LOG_EFFECT_SIZE="-0.004644905045763525" MODIFIED="2012-03-14 11:11:00 +0000" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.4781307498536531" STUDY_ID="STD-Aydemir-2011b" TOTAL_1="94" TOTAL_2="93" VAR="0.22860901395561659" WEIGHT="75.75842684465732"/>
<DICH_DATA CI_END="5.745326396949321" CI_START="0.014436777698833954" EFFECT_SIZE="0.288" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.7593147063693668" LOG_CI_START="-1.8405297308509052" LOG_EFFECT_SIZE="-0.5406075122407692" MODIFIED="2014-07-24 14:33:23 +0100" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="1.5271614918607077" STUDY_ID="STD-Mersal-2013" TOTAL_1="24" TOTAL_2="35" VAR="2.332222222222222" WEIGHT="19.302114879380284"/>
<DICH_DATA CI_END="202.5351702745371" CI_START="0.6864020281568748" EFFECT_SIZE="11.790697674418604" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3065004494267014" LOG_CI_START="-0.1634214419192026" LOG_EFFECT_SIZE="1.0715395037537494" MODIFIED="2012-03-14 11:11:25 +0000" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="1.4508443452871296" STUDY_ID="STD-Violaris-2010" TOTAL_1="42" TOTAL_2="38" VAR="2.10494931425164" WEIGHT="4.939458275962389"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.493115468101268" CI_START="0.6700538298707719" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2924865831842576" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.396742393224159" LOG_CI_START="-0.17389030613983467" LOG_EFFECT_SIZE="0.11142604354216216" METHOD="MH" MODIFIED="2012-03-16 16:58:58 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.44401274779346844" Q="0.0" RANDOM="NO" SCALE="2.607505960859053" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="85" WEIGHT="100.0" Z="0.7654346921437919">
<NAME>Bronchopulmonary dysplasia</NAME>
<GROUP_LABEL_1>Oral/topical non-absorbed</GROUP_LABEL_1>
<GROUP_LABEL_2>Systemic prophylaxis</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral/topical</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours systemic</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4931154681012684" CI_START="0.6700538298707718" EFFECT_SIZE="1.2924865831842576" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.39674239322415905" LOG_CI_START="-0.17389030613983472" LOG_EFFECT_SIZE="0.11142604354216216" MODIFIED="2012-03-16 16:57:09 +0000" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.3351924722838276" STUDY_ID="STD-Aydemir-2011b" TOTAL_1="86" TOTAL_2="85" VAR="0.11235399347574453" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.13213462139001292" CI_END="2.6016369263105092" CI_START="0.5760193983457204" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.224170468932897" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.41524668811257537" LOG_CI_START="-0.23956289079094217" LOG_EFFECT_SIZE="0.0878418986608166" METHOD="MH" MODIFIED="2012-03-16 15:58:18 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7162290653509262" P_Q="1.0" P_Z="0.5989899945307589" Q="0.0" RANDOM="NO" SCALE="6.28" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="136" TOTAL_2="131" WEIGHT="100.0" Z="0.5258535099535727">
<NAME>Necrotising enterocolitis</NAME>
<GROUP_LABEL_1>Oral/topical non-absorbed</GROUP_LABEL_1>
<GROUP_LABEL_2>Systemic prophylaxis</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral/topical</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours systemic</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.760174647297444" CI_START="0.4488266873926731" EFFECT_SIZE="1.113031914893617" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.44093656248474455" LOG_CI_START="-0.34792132768150913" LOG_EFFECT_SIZE="0.046507617401617726" MODIFIED="2012-03-16 15:51:26 +0000" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.4633790295931913" STUDY_ID="STD-Aydemir-2011b" TOTAL_1="94" TOTAL_2="93" VAR="0.2147201250667277" WEIGHT="71.85685960679392"/>
<DICH_DATA CI_END="5.889523983872165" CI_START="0.3860876563529597" EFFECT_SIZE="1.507936507936508" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7700801946968074" LOG_CI_START="-0.4133140830262752" LOG_EFFECT_SIZE="0.17838305583526606" MODIFIED="2012-03-16 15:47:39 +0000" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.6951316566306884" STUDY_ID="STD-Violaris-2010" TOTAL_1="42" TOTAL_2="38" VAR="0.4832080200501253" WEIGHT="28.143140393206085"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9786949876574855" CI_START="0.5124304636316024" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2354651162790697" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.47402603461513826" LOG_CI_START="-0.29036505965757536" LOG_EFFECT_SIZE="0.09183048747878142" METHOD="MH" MODIFIED="2014-01-06 19:08:59 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.6376961456462313" Q="0.0" RANDOM="NO" SCALE="3.299381906001905" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="85" WEIGHT="100.0" Z="0.4709224099802359">
<NAME>Retinopathy of prematurity</NAME>
<GROUP_LABEL_1>Oral/topical non-absorbed</GROUP_LABEL_1>
<GROUP_LABEL_2>Systemic prophylaxis</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral/topical</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours systemic</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9786949876574855" CI_START="0.5124304636316023" EFFECT_SIZE="1.2354651162790697" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.47402603461513826" LOG_CI_START="-0.2903650596575755" LOG_EFFECT_SIZE="0.09183048747878142" MODIFIED="2012-03-16 17:00:50 +0000" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.44900711257273296" STUDY_ID="STD-Aydemir-2011b" TOTAL_1="86" TOTAL_2="85" VAR="0.20160738714090287" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.625615672762847" CI_START="-7.625615672762847" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2012-03-16 17:03:46 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.7673705047508713" Q="0.0" RANDOM="NO" SCALE="8.471998172335429" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="85" UNITS="" WEIGHT="100.00000000000001" Z="0.2958161296009431">
<NAME>Length of stay in NICU (days)</NAME>
<GROUP_LABEL_1>Oral/topical non-absorbed</GROUP_LABEL_1>
<GROUP_LABEL_2>Systemic prophylaxis</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral/topical</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours systemic</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.625615672762847" CI_START="-7.625615672762847" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="46.0" MODIFIED="2012-03-16 17:03:41 +0000" MODIFIED_BY="[Empty name]" ORDER="24" SD_1="20.0" SD_2="24.0" SE="3.3804782766544985" STUDY_ID="STD-Aydemir-2011b" TOTAL_1="86" TOTAL_2="85" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-10-15 11:54:47 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-10-12 14:29:46 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAADOCAMAAADYBvzeAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-10-15 11:54:30 +0100" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Oral/topical non-absorbed antifungal prophylaxis vs placebo or nothing, outcome: 1.1 Incidence of invasive fungal infection.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAv0AAAFgCAMAAAAfCDYmAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-10-15 11:54:47 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Oral/topical non-absorbed antifungal prophylaxis vs placebo or nothing, outcome: 1.2 Mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAv0AAAFgCAMAAAAfCDYmAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-10-12 14:29:46 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.06" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Oral/topical non-absorbed antifungal prophylaxis vs placebo or nothing, outcome: 1.6 Length of stay in NICU (days).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA04AAACgCAMAAAAM2MzcAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2015-10-12 14:29:46 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-002.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Oral/topical non-absorbed prophylaxis vs. systemic antifungal prophylaxis, outcome: 2.1 Incidence of invasive fungal infection.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA4gAAACwCAMAAAB6r7ChAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2015-10-12 14:29:46 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-002.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Oral/topical non-absorbed prophylaxis vs. systemic antifungal prophylaxis, outcome: 2.2 Mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA48AAACwCAMAAACYc6vYAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2015-10-12 14:29:46 +0100" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-002.04" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Oral/topical non-absorbed prophylaxis vs. systemic antifungal prophylaxis, outcome: 2.4 Necrotising enterocolitis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA4gAAACgCAMAAAB5ebI6AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-10-12 20:17:28 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-10-12 20:17:28 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-07-24 15:19:20 +0100" MODIFIED_BY="[Empty name]">Update detailed electronic search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-10-12 20:17:28 +0100" MODIFIED_BY="[Empty name]">
<P>Information Specialist: Rocio Rodriguez Lopez [rocio.lopez@york.ac.uk]</P>
<P>Databases:</P>
<P>· MEDLINE (Ovid SP), 1946 &#8211; current;</P>
<P>· EMBASE (Ovid SP), 1974 &#8211; current;</P>
<P>· Cumulative Index to Nursing and Allied Health Literature Plus (CINAHL Plus) (EBSCO), 1937 &#8211; current;</P>
<P>· Cochrane Central Register of Controlled Trials (CENTRAL)</P>
<P>· The International Clinical Trials Registry Platform (<I>ICTRP</I>)</P>
<P>· Clinical Trials.gov</P>
<P>We applied a date limit July 2012 onwards to the bibliographic databases.</P>
<P>
<B>Database: Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations and Ovid MEDLINE(R)</B> &lt;1946 to Present&gt;</P>
<P>Searched online 17/07/14<BR/>
</P>
<P>Search Strategy:</P>
<P>--------------------------------------------------------------------------------</P>
<OL>
<LI>exp infant, premature/ (41486)</LI>
<LI>exp infant, low birth weight/ (26342)</LI>
<LI>Infant, Premature, Diseases/ (17779)</LI>
<LI>(preterm* or prematur* or (low and ("birth weight" or birthweight)) or ELBW or VLBW).ti,ab,hw. (189775)</LI>
<LI>or/1-4 (192144)</LI>
<LI>exp Mycoses/ (104604)</LI>
<LI>exp Fungi/ (302448)</LI>
<LI>(fungus or fungi or fungal or fungemia or fungaemia or aspergillosis or candid* or mycos?s).ti,ab,hw. (459779)</LI>
<LI>or/6-8 (604641)</LI>
<LI>and/5,9 (4150)</LI>
<LI>exp Antifungal Agents/ (134995)</LI>
<LI>exp azoles/ (523420)</LI>
<LI>(fungicid* or antifungal or azole*).ti,ab,rn. (66796)</LI>
<LI>(Fluconazole or Fluconazol or Diflucan or Triflucan or Elazor or Biozolene or Flucostat or Pritenzol or Biocanol or Flucazol or Flunizol).ti,ab,rn. (10206)</LI>
<LI>(Nystatin or Mycostatin or Nilstat or Nystop or Korostatin or Nystatinum or Biofanal or Nistatina or Nystaform or Nystatine).ti,ab,rn. (4594)</LI>
<LI>(Amphotericin or Amphotericine or Fungizone or Ambisome or Amphocin or Abelcet or Amfotericina or Ampho-Moronal or Amphotec).ti,ab,rn. (17395)</LI>
<LI>or/11-16 (655015)</LI>
<LI>and/10,17 (820)</LI>
<LI>limit 18 to ed=20120601-20140717 (100)</LI>
</OL>
<P>100 total results saved to Endnote library marked MEDLINE_17/07/2014 in Custom 4 field.</P>
<P>
<B>Database: EMBASE &lt;1974 to 2014 May 21&gt;</B>
</P>
<P>Searched online 17/07/14<BR/>
</P>
<P>Search Strategy:</P>
<P>--------------------------------------------------------------------------------</P>
<OL>
<LI>prematurity/ (72156)</LI>
<LI>exp low birth weight/ (39615)</LI>
<LI>(preterm* or pre-term* or pretermatur* or prematur* or (low and ("birth weight" or birthweight)) or ELBW or VLBW or LVW).ti,ab,hw. (232091)</LI>
<LI>or/1-3 (235476)</LI>
<LI>exp mycosis/ (146509)</LI>
<LI>fungal colonization/ (2535)</LI>
<LI>exp fungus/ (386952)</LI>
<LI>(fungus or fungi or fungal or fungemia or fungaemia or aspergillosis or candid* or mycos?s).ti,ab,hw. (564479)</LI>
<LI>or/5-8 (746245)</LI>
<LI>and/4,9 (5666)</LI>
<LI>exp antifungal agent/ (267508)</LI>
<LI>exp pyrrole derivative/ (57174)</LI>
<LI>(fungicid* or antifungal or azole*).ti,ab,rn. (51286)</LI>
<LI>(Fluconazole or Fluconazol or Diflucan or Triflucan or Elazor or Biozolene or Flucostat or Pritenzol or Biocanol or Flucazol or Flunizol).ti,ab,rn. (31540)</LI>
<LI>(Nystatin or Mycostatin or Nilstat or Nystop or Korostatin or Nystatinum or Biofanal or Nistatina or Nystaform or Nystatine).ti,ab,rn. (12465)</LI>
<LI>(Amphotericin or Amphotericine or Fungizone or Ambisome or Amphocin or Abelcet or Amfotericina or Ampho-Moronal or Amphotec).ti,ab,rn. (21126)</LI>
<LI>or/11-16 (335058)</LI>
<LI>and/10,17 (1268)</LI>
<LI>limit 18 to em=201220-201429 (225)</LI>
</OL>
<P>225 total results saved to Endnote library marked EMBASE_17/067/2014 in Custom 4 field.</P>
<P>
<B>CINAHL Plus</B>
<BR/>Searched online 17/07/14<BR/>
</P>
<P>Search Strategy:</P>
<P>--------------------------------------------------------------------------------</P>
<P>S18 S11 AND S17 34<BR/>S17 S12 OR S13 OR S14 OR S15 OR S16 5,975</P>
<P>S16 TX (Amphotericin or Amphotericine or Fungizone or Ambisome or Amphocin or Abelcet or Amfotericina or Ampho-Moronal or Amphotec) 1,244</P>
<P>S15 TX (Nystatin or Mycostatin or Nilstat or Nystop or Korostatin or Nystatinum or Biofanal or Nistatina or Nystaform or Nystatine) 195</P>
<P>S14 TX (Fluconazole or Fluconazol or Diflucan or Triflucan or Elazor or Biozolene or Flucostat or Pritenzol or Biocanol or Flucazol or Flunizol) 1,038</P>
<P>S13 TX (fungicid* or antifungal or azole*) 4,679</P>
<P>S12 (MH "Antifungal Agents+") 4,935</P>
<P>S11 S5 AND S10 535</P>
<P>S10 S6 OR S7 OR S8 OR S9 32,460</P>
<P>S9 TX (fungus or fungi or fungal or fungemia or fungaemia or aspergillosis or candid* or mycos?s) 27,232</P>
<P>S8 (MH "Fungi+") 7,672</P>
<P>S7 (MH "Mycosis Fungoides") 228</P>
<P>S6 (MH "Mycoses+") 10,176</P>
<P>S5 S1 OR S2 OR S3 OR S4 38,598</P>
<P>S4 TX (preterm* or pre-term* or pretermatur* or prematur* or (low and ("birth weight" or birthweight)) or ELBW or VLBW or LVW) 37,954</P>
<P>S3 (MH "Infant, Premature, Diseases") 2,438</P>
<P>S2 (MH "Infant, Low Birth Weight+") 8,128</P>
<P>S1 (MH "Infant, Premature") 13,445</P>
<P>34 total results saved to Endnote library marked CINAHL_18/07/2014 in Custom 4 field.</P>
<P>
<B>Cochrane Library (CENTRAL)</B>
<BR/>Searched online 17/07/14</P>
<P>Search Strategy:</P>
<P>--------------------------------------------------------------------------------</P>
<P>ID Search Hits</P>
<OL>
<LI>MeSH descriptor: [Infant, Premature] explode all trees 2753</LI>
<LI>MeSH descriptor: [Infant, Low Birth Weight] explode all trees 1814</LI>
<LI>MeSH descriptor: [Infant, Premature, Diseases] explode all trees 2186</LI>
<LI>(preterm* or pre-term* or pretermatur* or prematur* or (low and ("birth weight" or birthweight)) or ELBW or VLBW or LVW):ti,ab,kw (Word variations have been searched) 15350</LI>
<LI>#1 or #2 or #3 or #4 15681</LI>
<LI>MeSH descriptor: [Mycoses] explode all trees 2223</LI>
<LI>MeSH descriptor: [Fungi] explode all trees 1068</LI>
<LI>(fungus or fungi or fungal or fungemia or fungaemia or aspergillosis or candid* or mycos?s):ti,ab,kw (Word variations have been searched) 7137</LI>
<LI>#6 or #7 or #8 8166</LI>
<LI>#5 and #9 197</LI>
<LI>MeSH descriptor: [Antifungal Agents] explode all trees 1647</LI>
<LI>MeSH descriptor: [Azoles] explode all trees 29830</LI>
<LI>(fungicid* or antifungal or azole*):ti,ab,kw (Word variations have been searched) 2260</LI>
<LI>(Fluconazole or Fluconazol or Diflucan or Triflucan or Elazor or Biozolene or Flucostat or Pritenzol or Biocanol or Flucazol or Flunizol):ti,ab,kw (Word variations have been searched) 862</LI>
<LI>(Nystatin or Mycostatin or Nilstat or Nystop or Korostatin or Nystatinum or Biofanal or Nistatina or Nystaform or Nystatine):ti,ab,kw (Word variations have been searched) 336</LI>
<LI>(Amphotericin or Amphotericine or Fungizone or Ambisome or Amphocin or Abelcet or Amfotericina or Ampho-Moronal or Amphotec):ti,ab,kw (Word variations have been searched) 813</LI>
<LI>#11 or #12 or #13 or #14 or #15 or #16 31769</LI>
<LI>#10 and #17 Online Publication Date from Jan 2012 to Jul 2014, in Trials 7</LI>
</OL>
<P>7 total results saved to Endnote library marked CENTRAL_17/07/2014 in Custom 4 field.</P>
<P>
<B>The International Clinical Trials Registry Platform (<I>ICTRP</I>)</B>
<BR/>http://www.who.int/ictrp/en/<BR/>Searched online 17/07/14<BR/>Search Strategy:</P>
<P>--------------------------------------------------------------------------------</P>
<P>(premature OR preterm OR "low birth weight") AND ( Nystatin OR Fluconazole OR Amphotericin)</P>
<P>5 total results saved to Endnote library marked <I>ICTRP 17/07/2014 </I>in Custom 4 field.</P>
<P>
<B>ClinicalTrials.gov<BR/>
</B>https://clinicaltrials.gov/<B>
<BR/>
</B>Searched online 17/07/14</P>
<P>Search Strategy:</P>
<P>--------------------------------------------------------------------------------</P>
<P>(premature OR preterm OR "low birth weight") AND ( Nystatin OR Fluconazole OR Amphotericin)</P>
<P>7 total results saved to Endnote library marked CLINICALTRIALS.GOV 17/07/2014 in Custom 4 field.</P>
<P>
<B>Total Results</B>
</P>
<TABLE COLS="4" ROWS="8">
<TR>
<TD VALIGN="TOP">
<P>
<B>Database</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Results</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>After deduplication</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Custom 4 field</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE and MEDLINE In-Process</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>100</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>90</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>MEDLINE 17/07/2014</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD VALIGN="TOP">
<P>225</P>
</TD>
<TD VALIGN="TOP">
<P>170</P>
</TD>
<TD VALIGN="TOP">
<P>EMBASE 17/07/2014</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CINAHL</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>CINAHL 17/07/2014</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>CENTRAL 17/07/2014</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>The International Clinical Trials Registry Platform (<I>ICTRP</I>)</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>
<I>ICTRP 17/07/2014</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<BR/>ClinicalTrials.gov</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>CLINICALTRIALS.GOV 17/07/2014</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Total</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>378</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>287</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-10-12 14:47:12 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2015-09-03 18:04:52 +0100" MODIFIED_BY="[Empty name]">Addendum to search (May 2015)</TITLE>
<APPENDIX_BODY MODIFIED="2015-10-12 14:47:12 +0100" MODIFIED_BY="[Empty name]">
<P>Search Date: May 19, 2015 (N = 16)</P>
<P>Search Terms: (nystatin OR nystan OR mycostatin OR nilstat OR nystex OR miconazole OR daktarin OR ketoconazole OR clotrimazole) AND</P>
<P>Plus the following database-specific terms:</P>
<P>PubMed: ((infant, newborn[MeSH] OR newborn OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW or infan* or neonat*) AND (randomized controlled trial [pt] OR controlled clinical trial [pt] OR Clinical Trial[ptyp] OR randomized [tiab] OR placebo [tiab] OR clinical trials as topic [mesh: noexp] OR randomly [tiab] OR trial [ti]) NOT (animals [mh] NOT humans [mh]))</P>
<P>EMBASE: (infant, newborn or newborn or neonate or neonatal or premature or very low birth weight or low birth weight or VLBW or LBW or Newborn or infan* or neonat*) AND (human not animal) AND (randomized controlled trial or controlled clinical trial or randomized or placebo or clinical trials as topic or randomly or trial or clinical trial)</P>
<P>CINAHL: (infant, newborn OR newborn OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW or Newborn or infan* or neonat*) AND (randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR clinical trials as topic OR randomly OR trial OR PT clinical trial)</P>
<P>Cochrane Library: (infant or newborn or neonate or neonatal or premature or very low birth weight or low birth weight or VLBW or LBW)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>